Cell Expansion Systems (CES's) may be used to expand and differentiate a variety of cell types that may be used for both research and therapeutic purposes. As one example, CD34+ progenitor cells hematological progenitor stem cells (HSC's) have been identified as possible treatments in diseases such as cancers (e.g., lymphoma, leukemia, myeloma, etc.). HSC's may be collected from bone marrow, cord blood, and or peripheral blood. It has been suggested that a minimum number of HSC's should be given as an effective dose. Accordingly, the HSC's may be grown from an initial amount to at least an amount that may be considered an effective dose.
Embodiments have been made in light of these and other considerations. However, the relatively specific problems discussed above do not limit the applicability of the embodiments of the present disclosure.
The summary is provided to introduce aspects of some embodiments in a simplified form, and is not intended to identify key or essential elements, nor is it intended to limit the scope of the claims.
Embodiments relate to cell expansion systems (CES's) and methods of growing cells in a bioreactor of a cell expansion system. Embodiments provide methods for expanding cells in a bioreactor, such as a hollow fiber bioreactor. Embodiments may provide for introducing cells, e.g., hematopoietic stem cells (HSC's) (for example, CD34+ cells) into a hollow fiber bioreactor, wherein the hollow fiber bioreactor includes a plurality of hollow fibers. Embodiments may provide for exposing the first plurality of cells to growth conditions. The growth conditions may include exposing the first plurality of cells to a combination of growth factors in the hollow fiber bioreactor. In embodiments, the growth conditions may include, but are not limited to, co-cultured cells and a combination of growth factors. After exposing the cells to the growth conditions, the cells may be expanded to generate a second plurality of expanded cells. The second plurality of expanded cells may then be removed from the bioreactor.
Non-limiting and non-exhaustive embodiments are described with reference to the following figures.
The principles of the present disclosure may be further understood by reference to the following detailed description and the embodiments depicted in the accompanying drawings. It should be understood that although specific features are shown and described below with respect to detailed embodiments, the present disclosure is not limited to the embodiments described below.
Reference will now be made in detail to the embodiments illustrated in the accompanying drawings and described below. Wherever possible, the same reference numerals are used in the drawings and the description to refer to the same or like parts.
Referring to
According to embodiments of the present disclosure, fluid in a first circulation path enters hollow fiber bioreactor 100 through IC inlet port 108 at a first longitudinal end 112 of the hollow fiber bioreactor 100, passes into and through the intracapillary side (referred to in various embodiments as the intracapillary (“IC”) side or “IC space” of a hollow fiber membrane) of a plurality of hollow fibers 116, and out of hollow fiber bioreactor 100 through IC outlet port 120 located at a second longitudinal end 124 of the hollow fiber bioreactor 100. The fluid path between the IC inlet port 108 and the IC outlet port 120 defines the IC portion 126 of the hollow fiber bioreactor 100. Fluid in a second circulation path flows in the hollow fiber bioreactor 100 through EC inlet port 128, comes in contact with the extracapillary side or outside (referred to as the “EC side” or “EC space” of the membrane) of the hollow fibers 116, and exits hollow fiber bioreactor 100 via EC outlet port 132. The fluid path between the EC inlet port 128 and the EC outlet port 132 comprises the EC portion 136 of the hollow fiber bioreactor 100. Fluid entering hollow fiber bioreactor 100 via the EC inlet port 128 may be in contact with the outside of the hollow fibers 116. Small molecules (e.g., ions, water, oxygen, lactate, etc.) may diffuse through the hollow fibers 116 from the interior or IC space of the hollow fiber to the exterior or EC space, or from the EC space to the IC space. Large molecular weight molecules, such as growth factors, may be too large to pass through the hollow fiber membrane, and remain in the IC space of the hollow fibers 116. The media may be replaced as needed, in embodiments. Media may also be circulated through an oxygenator or gas transfer module to exchange gasses as needed (see e.g., cell expansion systems 500 (
The material used to make the hollow fiber membrane may be any biocompatible polymeric material which is capable of being made into hollow fibers. One material which may be used is a synthetic polysulfone-based material, according to an embodiment of the present disclosure. In order for the cells to adhere to the surface of the hollow fibers, the surface may be modified in some way, either by coating at least the cell growth surface with a protein, e.g., a glycoprotein such as fibronectin or collagen, or by exposing the surface to radiation. Gamma treating the membrane surface may allow for attachment of adherent cells without additionally coating the membrane with fibronectin or the like. Bioreactors made of gamma treated membranes may be reused. Other coatings and/or treatments for cell attachment may be used in accordance with embodiments of the present disclosure.
Turning to
Next,
In accordance with embodiments, a shaft or rocker control 258 for rotating the bioreactor 100 is shown in
Turning to
In embodiments, the shaft fitting 402 and the spring member 404 connect to mechanisms of a cell expansion system that rotate the bioreactor 100. For example, in some embodiments, the cell expansion system may be part of a QUANTUM® Cell Expansion System (CES), manufactured by Terumo BCT, Inc. of Lakewood, CO, which provides for rotation of a bioreactor. Examples of cell expansion systems that provide for rotation of the bioreactor are described in at least: U.S. Pat. No. 8,399,245, issued Mar. 19, 2013, entitled “ROTATION SYSTEM FOR CELL GROWTH CHAMBER OF A CELL EXPANSION SYSTEM AND METHOD OF USE THEREFOR;” U.S. Pat. No. 8,809,043, issued Feb. 13, 2013, entitled “ROTATION SYSTEM FOR CELL GROWTH CHAMBER OF A CELL EXPANSION SYSTEM AND METHOD OF USE THEREFOR;” and U.S. Pat. No. 9,057,045, issued Jun. 16, 2015, entitled “METHOD OF LOADING AND DISTRIBUTING CELLS IN A BIOREACTOR OF A CELL EXPANSION SYSTEM;” all three of which are hereby incorporated by reference in their entirety as if set forth herein in full.
According to embodiments, the premounted fluid conveyance assembly 400 includes tubing 408A, 408B, 408C, 408D, 408E, etc., and various tubing fittings to provide the fluid paths shown in
With regard to the IC loop 502, samples of media may be obtained from sample port 516 or sample coil 518 during operation. Pressure/temperature gauge 520 disposed in first fluid circulation path 502 allows detection of media pressure and temperature during operation. Media then returns to IC inlet port 501A to complete fluid circulation path 502. Cells grown/expanded in hollow fiber bioreactor 501 may be flushed out of hollow fiber bioreactor 501 into harvest bag 599 through valve 598 or redistributed within the hollow fibers for further growth.
Fluid in second fluid circulation path 504 enters hollow fiber bioreactor 501 via EC inlet port 501C, and leaves hollow fiber bioreactor 501 via EC outlet port 501D. Media in the EC loop 504 may be in contact with the outside of the hollow fibers in the hollow fiber bioreactor 501, thereby allowing diffusion of small molecules into and out of the hollow fibers.
Pressure/temperature gauge 524 disposed in the second fluid circulation path 504 allows the pressure and temperature of media to be measured before the media enters the EC space of hollow fiber bioreactor 501. Pressure gauge 526 allows the pressure of media in the second fluid circulation path 504 to be measured after it leaves hollow fiber bioreactor 501. With regard to the EC loop, samples of media may be obtained from sample port 530 or a sample coil during operation.
In embodiments, after leaving EC outlet port 501D of hollow fiber bioreactor 501, fluid in second fluid circulation path 504 passes through EC circulation pump 528 to oxygenator or gas transfer module 532. EC circulation pump 528 may also pump the fluid in opposing directions. Second fluid flow path 522 may be fluidly associated with oxygenator or gas transfer module 532 via oxygenator inlet port 534 and oxygenator outlet port 536. In operation, fluid media flows into oxygenator or gas transfer module 532 via oxygenator inlet port 534, and exits oxygenator or gas transfer module 532 via oxygenator outlet port 536. Oxygenator or gas transfer module 532 adds oxygen to and removes bubbles from media in the CES 500. In various embodiments, media in second fluid circulation path 504 may be in equilibrium with gas entering oxygenator or gas transfer module 532. The oxygenator or gas transfer module 532 may be any appropriately sized oxygenator or gas transfer device. Air or gas flows into oxygenator or gas transfer module 532 via filter 538 and out of oxygenator or gas transfer device 532 through filter 540. Filters 538 and 540 reduce or prevent contamination of oxygenator or gas transfer module 532 and associated media. Air or gas purged from the CES 500 during portions of a priming sequence may vent to the atmosphere via the oxygenator or gas transfer module 532.
In the configuration depicted for CES 500, fluid media in first fluid circulation path 502 and second fluid circulation path 504 flows through hollow fiber bioreactor 501 in the same direction (a co-current configuration). The CES 500 may also be configured to flow in a counter-current configuration.
In accordance with at least one embodiment, media, including cells (from bag 562), and fluid media from bag 546 may be introduced to first fluid circulation path 502 via first fluid flow path 506. Fluid container 562 (e.g., Cell Inlet Bag or Saline Priming Fluid for priming air out of the system) may be fluidly associated with the first fluid flow path 506 and the first fluid circulation path 502 via valve 564.
Fluid containers, or media bags, 544 (e.g., Reagent) and 546 (e.g., IC Media) may be fluidly associated with either first fluid inlet path 542 via valves 548 and 550, respectively, or second fluid inlet path 574 via valves 548, 550, and 570. First and second sterile sealable input priming paths 508 and 509 are also provided. An air removal chamber (ARC) 556 may be fluidly associated with first circulation path 502. The air removal chamber 556 may include one or more ultrasonic sensors including an upper sensor and lower sensor to detect air, a lack of fluid, and/or a gas/fluid interface, e.g., an air/fluid interface, at certain measuring positions within the air removal chamber 556. For example, ultrasonic sensors may be used near the bottom and/or near the top of the air removal chamber 556 to detect air, fluid, and/or an air/fluid interface at these locations. Embodiments provide for the use of numerous other types of sensors without departing from the spirit and scope of the present disclosure. For example, optical sensors may be used in accordance with embodiments of the present disclosure. Air or gas purged from the CES 500 during portions of the priming sequence or other protocols may vent to the atmosphere out air valve 560 via line 558 that may be fluidly associated with air removal chamber 556.
EC media (from bag 568) or wash solution (from bag 566) may be added to either the first or second fluid flow paths. Fluid container 566 may be fluidly associated with valve 570 that may be fluidly associated with first fluid circulation path 502 via distribution valve 572 and first fluid inlet path 542. Alternatively, fluid container 566 may be fluidly associated with second fluid circulation path 504 via second fluid inlet path 574 and EC inlet path 584 by opening valve 570 and closing distribution valve 572. Likewise, fluid container 568 may be fluidly associated with valve 576 that may be fluidly associated with first fluid circulation path 502 via first fluid inlet path 542 and distribution valve 572. Alternatively, fluid container 568 may be fluidly associated with second fluid inlet path 574 by opening valve 576 and closing valve distribution 572. An optional heat exchanger 552 may be provided for media reagent or wash solution introduction.
In the IC loop, fluid may be initially advanced by the IC inlet pump 554. In the EC loop, fluid may be initially advanced by the EC inlet pump 578. An air detector 580, such as an ultrasonic sensor, may also be associated with the EC inlet path 584.
In at least one embodiment, first and second fluid circulation paths 502 and 504 are connected to waste line 588. When valve 590 is opened, IC media may flow through waste line 588 and to waste or outlet bag 586. Likewise, when valve 582 is opened, EC media may flow through waste line 588 to waste or outlet bag 586.
In embodiments, cells may be harvested via cell harvest path 596. Here, cells from hollow fiber bioreactor 501 may be harvested by pumping the IC media containing the cells through cell harvest path 596 and valve 598 to cell harvest bag 599.
Various components of the CES 500 may be contained or housed within a machine or housing, such as cell expansion machine 202 (
Turning to
Media flows through IC circulation pump 612 which may be used to control the rate of media flow or rate of circulation. IC circulation pump 612 may pump the fluid in a first direction (e.g. counter clockwise) or second direction opposite the first direction (e.g., clockwise). Exit port 601B may be used as an inlet in the reverse direction. Media entering the IC loop may flow through valve 614. As those skilled in the art will appreciate, additional valves and/or other devices may be placed at various locations to isolate and/or measure characteristics of the media along portions of the fluid paths. Samples of media may be obtained from sample coil 618 during operation. Media then returns to IC inlet port 601A to complete fluid circulation path 602.
Cells grown/expanded in hollow fiber bioreactor 601 may be flushed out of hollow fiber bioreactor 601 into harvest bag 699 through valve 698 and line 697. Alternatively, when valve 698 is closed, the cells may be redistributed within hollow fiber bioreactor 601 for further growth. It is to be understood that the schematic shown represents one possible configuration for various elements of the CES 600, and modifications to the schematic shown are within the scope of the one or more present embodiments.
Fluid in second fluid circulation path 604 enters hollow fiber bioreactor 601 via EC inlet port 601C and leaves hollow fiber bioreactor 601 via EC outlet port 601D. Media in the EC loop may be in contact with the outside of the hollow fibers in the hollow fiber bioreactor 601, thereby allowing diffusion of small molecules into and out of the hollow fibers that may be within chamber 601, according to an embodiment.
Pressure/temperature sensor 624 disposed in the second fluid circulation path 604 allows the pressure and temperature of media to be measured before the media enters the EC space of the hollow fiber bioreactor 601. Sensor 626 allows the pressure and/or temperature of media in the second fluid circulation path 604 to be measured after it leaves the hollow fiber bioreactor 601. With regard to the EC loop, samples of media may be obtained from sample port 630 or a sample coil during operation.
After leaving EC outlet port 601D of hollow fiber bioreactor 601, fluid in second fluid circulation path 604 passes through EC circulation pump 628 to oxygenator or gas transfer module 632. EC circulation pump 628 may also pump the fluid in opposing directions, according to embodiments. Second fluid flow path 622 may be fluidly associated with oxygenator or gas transfer module 632 via an inlet port 632A and an outlet port 632B of oxygenator or gas transfer module 632. In operation, fluid media flows into oxygenator or gas transfer module 632 via inlet port 632A, and exits oxygenator or gas transfer module 632 via outlet port 632B. Oxygenator or gas transfer module 632 adds oxygen to and removes bubbles from media in the CES 600.
In various embodiments, media in second fluid circulation path 604 may be in equilibrium with gas entering oxygenator or gas transfer module 632. The oxygenator or gas transfer module 632 may be any appropriately sized device useful for oxygenation or gas transfer. Air or gas flows into oxygenator or gas transfer module 632 via filter 638 and out of oxygenator or gas transfer device 632 through filter 640. Filters 638 and 640 reduce or prevent contamination of oxygenator or gas transfer module 632 and associated media. Air or gas purged from the CES 600 during portions of a priming sequence may vent to the atmosphere via the oxygenator or gas transfer module 632.
In the configuration depicted for CES 600, fluid media in first fluid circulation path 602 and second fluid circulation path 604 flows through hollow fiber bioreactor 601 in the same direction (a co-current configuration). The CES 600 may also be configured to flow in a counter-current configuration.
In accordance with at least one embodiment, media, including cells (from a source such as a cell container, e.g. a bag) may be attached at attachment point 662, and fluid media from a media source may be attached at attachment point 646. The cells and media may be introduced into first fluid circulation path 602 via first fluid flow path 606. Attachment point 662 may be fluidly associated with the first fluid flow path 606 via valve 664, and attachment point 646 may be fluidly associated with the first fluid flow path 606 via valve 650. A reagent source may be fluidly connected to point 644 and be associated with fluid inlet path 642 via valve 648, or second fluid inlet path 674 via valves 648 and 672.
Air removal chamber (ARC) 656 may be fluidly associated with first circulation path 602. The air removal chamber 656 may include one or more sensors including an upper sensor and lower sensor to detect air, a lack of fluid, and/or a gas/fluid interface, e.g., an air/fluid interface, at certain measuring positions within the air removal chamber 656. For example, ultrasonic sensors may be used near the bottom and/or near the top of the air removal chamber 656 to detect air, fluid, and/or an air/fluid interface at these locations. Embodiments provide for the use of numerous other types of sensors without departing from the spirit and scope of the present disclosure. For example, optical sensors may be used in accordance with embodiments of the present disclosure. Air or gas purged from the CES 600 during portions of a priming sequence or other protocol(s) may vent to the atmosphere out air valve 660 via line 658 that may be fluidly associated with air removal chamber 656.
An EC media source may be attached to EC media attachment point 668 and a wash solution source may be attached to wash solution attachment point 666, to add EC media and/or wash solution to either the first or second fluid flow path. Attachment point 666 may be fluidly associated with valve 670 that may be fluidly associated with first fluid circulation path 602 via valve 672 and first fluid inlet path 642. Alternatively, attachment point 666 may be fluidly associated with second fluid circulation path 604 via second fluid inlet path 674 and second fluid flow path 684 by opening valve 670 and closing valve 672. Likewise, attachment point 668 may be fluidly associated with valve 676 that may be fluidly associated with first fluid circulation path 602 via first fluid inlet path 642 and valve 672. Alternatively, fluid container 668 may be fluidly associated with second fluid inlet path 674 by opening valve 676 and closing valve distribution 672.
In the IC loop, fluid may be initially advanced by the IC inlet pump 654. In the EC loop, fluid may be initially advanced by the EC inlet pump 678. An air detector 680, such as an ultrasonic sensor, may also be associated with the EC inlet path 684.
In at least one embodiment, first and second fluid circulation paths 602 and 604 are connected to waste line 688. When valve 690 is opened, IC media may flow through waste line 688 and to waste or outlet bag 686. Likewise, when valve 692 is opened, EC media may flow to waste or outlet bag 686.
After cells have been grown in hollow fiber bioreactor 601, they may be harvested via cell harvest path 697. Here, cells from hollow fiber bioreactor 601 may be harvested by pumping the IC media containing the cells through cell harvest path 697, with valve 698 open, into cell harvest bag 699.
Various components of the CES 600 may be contained or housed within a machine or housing, such as cell expansion machine 202 (
In one specific embodiment of using CES 600, hematopoietic stem cells (HSC's), e.g., CD34+ cells, may be expanded in an embodiment of CES 600. In this embodiment, HSC's (including CD34+ cells), which may be collected using a leukapheresis process or a manual process (e.g., umbilical cords), may be introduced into the bioreactor 601. The HSC's (including CD34+ cells) may be introduced into the bioreactor 601 through path 602.
In some embodiments, the HSC's (including CD34+ cells) may be subjected to a selection process (e.g., a purification process) before introduction into bioreactor 601. The process may involve the use of a centrifuge, purification column, magnetic selection, chemical selection, etc. Some examples of cell selection/purification procedures include use of isolation columns from, for example, Miltenyi Biotec of Bergisch Gladbach, Germany. In one example, cord blood is first subjected to a cell selection process that selects for HSC's (including CD34+ cells) before the cells are introduced into the bioreactor 601. Other examples may utilize apheresis machines to deplete other cells that may be included with the HSC's (including CD34+ cells) when originally collected. For example, the HSC's may be sourced from cord blood, bone marrow, or peripheral blood. After initial collection, but before being introduced into the bioreactor 601, a volume of HSC's including CD34+ cells may be processed to deplete red blood cells, specific leukocytes, granulocytes, and/or other cells from the volume. These are merely some examples, and embodiments of the present invention are not limited thereto.
In other embodiments, the HSC's (including CD34+ cells) may be added directly to the bioreactor 601 after collection without any additional purification. For example, cord blood (with HSC's) may be added to the bioreactor. In addition to a number of proteins and other bioactive molecules, the cord blood may include HSC's (including CD34+ cells), red blood cells, platelets, granulocytes, and/or leukocytes.
It is noted that in some embodiments, the HSC's may be added to bioreactor 601, after a priming step. As may be appreciated, the cells being expanded may not be adherent and therefore it may not be required that they adhere to the hollow fiber walls of bioreactor 601 for expansion/proliferation. In these embodiments, it may be unnecessary to coat the inside of the hollow fibers with a coating to promote adhesion, e.g., fibronectin. In these embodiments, the HSC's (including CD34+ cells) (purified or unpurified) may be introduced into the bioreactor 601 after a priming step and without a bioreactor coating step. If the cells were adherent cells, a coating step may be performed after the priming step and before introduction of the HSC's.
Once in the bioreactor 601, the cells may be exposed to growth factors, activators, hormones, reagents, proteins, and/or other bioactive molecules that may aid in the expansion of the cells. In one example, a co-culture cell line may have been previously grown/introduced, in the bioreactor 601, to optimize the conditions for growing the HSC's (including CD34+ cells). In one specific embodiment, human mesenchymal stem cells (hMSC's) may be co-cultured with the HSC's (including CD34+ cells) to promote growth of CD34+ cells. Without being bound by theory, it is believed that MSC's may emit factors (e.g., SDF-1 factors) that interact with HSC's (e.g., CD34+ cells) and promote proliferation of these cells. In some embodiments, use of the co-cultured hMSC's may involve a growing process that is performed initially, under conditions optimized for proliferating the hMSC's, before the HSC's (including CD34+ cells) are introduced into the bioreactor 601. The hMSC's may be derived in embodiments from bone marrow, peripheral blood, cord cells, adipose tissue, and/or molar tissue.
In addition to co-culture cells, a supplement including one or more growth factors, activators, hormones, reagents, proteins, and/or other bioactive molecules may be added to bioreactor 601 to grow and expand the HSC's. The supplement may be added as a single volume addition or over a period of time (e.g., continuously, intermittently, or on a regular schedule). In one embodiment, a combination of cytokines and/or other proteins, e.g., recombinant cytokines, hormones, etc., may be included as part of the supplement. As one example, a supplement may include one or more of: recombinant human Flt3 ligand (rhFlt-3L), recombinant human stem cell factor (rhSCF), recombinant human thrombopoietin (rhTPO), recombinant human (rh) Glial-derived neurotrophic factors and/or combinations thereof. One example of a supplement that may be used with embodiments is STEMCELL2MAX™ supplement (stemcell2MAX, Cantanhede, Portugal).
It is noted that in some embodiments, the combination of factors may be included in the media in which the cells are suspended. For example, the HSC's may be suspended in media and introduced into the bioreactor in the media. In embodiments, the media may include a combination of growth factors that aid in proliferation of the HSC's.
After the cells have been introduced into the bioreactor with the supplement, co-culture cells, and/or other material for expanding the cells, the cells are allowed to expand in bioreactor 601. During the expansion, there may be a number of materials that may be added or removed from bioreactor 601. As one example, additional proteins (e.g., cytokines) may be may be added to bioreactor 601. In some embodiments, more than one protein or other bioactive agent may be used. The additional material may be added individually, at the same time, at different times, or may be combined and added in combination.
It is noted that some embodiments may provide for adding material more directly into the bioreactor 601, such as through port 618. In other embodiments, however, the materials may be added in a location, e.g., through path 606, so that the materials may be perfused more slowly into bioreactor 601.
In addition to materials for aiding in growing the HSC's (including CD34+ cells), the HSC's may also be fed, such as by addition of a media that may include a number of nutrients. In some embodiments, the media may be commercially available media that may include serum. In other embodiments, the media may be serum free and include other additives. The media may be modified by the addition of other materials, some non-limiting examples including salts, serum, proteins, reagents, bioactive molecules, nutrients, etc. One example of media that may be used to feed the HSC's (including CD34+ cells) includes CELLGRO® serum free media (CellGenix, Freiburg, Germany).
In some embodiments, while the co-culture cells are located in the IC space, feeding may occur in the EC space. Feeding through the EC space may, in embodiments, reduce the amount of force that may be felt by the cells from circulating fluid in the IC space. Circulation of media in the EC space may, in embodiments, provide sufficient nutrients for the expansion of the HSC's (including CD34+ cells).
As part of the expansion of the HSC's (including CD34+ cells), other conditions such as temperature, pH, oxygen concentration, carbon dioxide concentration, waste concentration, metabolite concentration etc. may also be controlled in bioreactor 601. In some embodiments, the flow rates of the EC side, e.g., path 604 may be used to control various parameters. For example, if it is desired to reduce waste or metabolite concentrations on the IC side, where the cells are growing, flow rate on the EC side may be increased to ensure that the waste and/or metabolites are removed from the IC side by migration through the hollow fibers from the IC side to the EC side.
After the CD34+ cells have been expanded, the cells may be removed from the bioreactor 601. The CD34+ cells may be collected in container 699. In embodiments, the collected CD34+ cells may be administered to a patient to reestablish hematopoiesis. Some non-limiting examples including patients undergoing treatment for various cancers, e.g., leukemia, myelodysplasia, non-Hodgkin lymphoma, etc., which may effect hematopoiesis. The cells may be administered with other compounds or molecules.
In some embodiments, use of CES 600 may provide advantages in growing HSC's (including CD34+ cells) over conventional processes. For example, the use of hollow fibers allows close cell to cell communication, which may enhance the growth of the CD34+ cells to start and continue to proliferate. Also, the use of a hollow fiber bioreactor, such as bioreactor 601, may provide a large surface area for cell growth, which may yield a higher concentration or higher volume of CD34+ cells.
Further, the conditions in bioreactor 601 may be controlled using a number of different components of the CES 600, including IC flow rates and EC flow rates. Also, CES 600 provides various locations for the addition of materials, which allows more direct, or indirect, e.g., perfusion, of cytokines into bioreactor 601.
Additionally, CES 600 provides a closed system. That is, the steps for growing the CD34+ cells may be performed without direct exposure to the ambient environment, which may contaminate the cells, or be contaminated by the cells or materials used in growing the cells. It is also believed that some embodiments may provide for using a smaller starting concentration of CD34+ cells for expansion, compared to other methods/systems. In these embodiments, CD34+ cells may also be expanded to yield larger amounts than from other methods/systems. It is also believed that some embodiments may provide for shortening the time for growing an effective dose of CD34+ cells.
Flow 700 starts at step 704 and proceeds to optional step 708 where cells (e.g., HSC's including CD34+ cells) may be collected/prepared. As one example, step 708 may involve an apheresis process, e.g., a leukapheresis process. In one specific embodiment, an apheresis process is performed as part of step 708. Devices capable of collecting the cells include in an apheresis process include the SPECTRA OPTIA® apheresis system, COBE® spectra apheresis system, and the TRIMA ACCEL® automated blood collection system, all manufactured by Terumo BCT, of Lakewood, Colorado.
In other embodiments, optional step 708 may involve thawing or otherwise preparing cells (e.g., from cord blood). In some embodiments, the preparation of the cord blood cells may involve processing the cord blood cells through a selection process that selects CD34+ cells. The process may be either a positive or a negative selection process. The process may involve the use of purification columns, magnetic columns, functionalized magnetic beads, reagents, or other materials that separate CD34+ cells from other cells. As one example, the selection process may involve the use of magnetic beads, functionalized with antigens, and devices such as the CLINIMACS PRODIGY® system (Miltenyi Biotec, Bergisch Gladbach, Germany) that utilizes a magnetic column to complete the separation.
In other embodiments, apheresis machines may be used to deplete other cells that may be included with the cells when originally collected. For example, the cells may be sourced from cord blood, bone marrow, or peripheral blood. After initial collection, but before being introduced into a bioreactor, a volume of target cells may be processed to deplete red blood cells, specific leukocytes, granulocytes, and/or other cells from the volume before introduction into a bioreactor. This is merely one example and embodiments may utilize other materials and systems to effect the separation.
Flow 700 passes from step 708 to step 712, where cells may be introduced into a cell expansion system, in particular, a bioreactor of a cell expansion system. As noted above, in some embodiments, flow 700 may begin at step 712. In embodiments, the bioreactor may be a hollow fiber bioreactor such as bioreactor 100 (
After step 712, flow 700 passes to step 716 where the cells are exposed to one or more growth conditions. As may be appreciated, certain cell types require specific growth conditions to expand. The growth conditions may for example include exposure to certain proteins. One example of this type of cell includes CD34+ cells. Step 716 provides for exposing cells to any necessary growth factors, proteins, reagents, nutrients, etc. that may promote cell expansion and growth.
Step 716 may involve a number of steps that may be performed as part of step 716, or precede step 716. For example, in some embodiments, step 720 may be performed to grow co-culture cells that may generate material that promotes growth of the target cell line. In one embodiment, step 720 may be performed prior to step 716, or even prior to step 708. In one specific example, human mesenchymal stem cells (hMSC's) may be grown in the bioreactor. In these embodiments, step 720 may involve a number of steps (e.g., collecting hMSC's from bone marrow, peripheral blood, cord cells, adipose tissue, and/or molar tissue) that result in co-culture cells being present in the bioreactor during step 716. As may be appreciated, these steps may be performed prior to step 712.
With respect to growing the co-culture cells, several steps for conditioning the bioreactor for growing the co-culture cells may be performed. In embodiments, the steps may include priming the bioreactor, coating the bioreactor with materials that promote the attachment of the co-culture cells (e.g., when the co-culture cells are adherent cells), washing to remove materials prior to introduction of the co-culture cells into the bioreactor, attaching the co-culture cells, and expanding the co-culture cells.
In other embodiments, step 716 may involve step 724, where growth factors may be added to the bioreactor. As may be appreciated, in some embodiments, one or more growth factors, e.g., cytokines, may be added to promote the proliferation of cells. As one example, when growing CD34+ cells, the growth factor(s) may include one or more of: recombinant human Flt3 ligand (rhFlt-3L), recombinant human stem cell factor (rhSCF), recombinant human thrombopoietin (rhTPO), recombinant human (rh) Glial-derived neurotrophic factors, and combinations thereof. This is merely one example and in other embodiments, different growth factors, combination of growth factors, or other proteins may be used as part of step 724.
In one embodiment, at least a portion of the growth factors may be introduced with the cells at step 712. For example, the media in which the cells are in when introduced into the bioreactor may be conditioned with a combination of growth factors including one or more of recombinant human Flt3 ligand (rhFlt-3L), recombinant human stem cell factor (rhSCF), recombinant human thrombopoietin (rhTPO), recombinant human (rh) Glial-derived neurotrophic factors, and combinations thereof. In these embodiments, step 716, and optional step 724, may involve supplementing growth factors that may have already been added to the bioreactor with the cells.
After step 716, flow may pass to step 728, where cells are expanded, i.e., proliferated. Step 728 may involve a number of sub-steps. For example, at sub-step 732, the cells may be exposed to additional growth factors, proteins, bioactive molecules, etc. The exposure may provide for the cells to continue to proliferate.
In embodiments, step 728 may occur during a period of time of several hours, several days, or even several weeks. During this period of time, the various sub-steps (e.g., 732, 736, and/or 740) may be performed at various times during this period. For example, during the period, additional substances such as growth factors may be perfused or directly injected into the bioreactor to supplement and continue to expose the cells and promote proliferation.
Step 728 may also involve a feeding cells step 736. Step 736 may involve adding various nutrients, including glucose, phosphates, salts, etc. Step 736 may in embodiments involve sensing a concentration of a nutrient and in response to a relatively low concentration, adding nutrient(s) to the bioreactor. Step 736 may involve the use of a processor, pumps, valves, fluid conduit, etc. to add nutrients to feed the cells. Alternatively, the additions of nutrients, such as glucose may be added based on a predetermined schedule.
In some embodiments, step 728 may involve circulating media in the EC space. The media may include nutrients necessary for expansion of the CD34+ cells. Feeding through the EC space may, in embodiments, reduce the amount of force that may be felt by the cells if media is circulated in the IC space. Circulation of media in the EC space may, in embodiments, provide sufficient nutrients (e.g., glucose) for the expansion of the HSC's (including CD34+ cells) through diffusion of the nutrients through hollow fibers. In other embodiments, step 728 may involve circulating media, with nutrients (e.g., glucose), in the IC space for more direct feeding.
Step 740 may involve controlling the growth environment of the bioreactor. As may be appreciated, in addition to nutrients, the environment for optimizing growth of cells may involve a number of different parameters. For example, the temperature, pH, oxygen concentration, carbon dioxide concentration, waste concentration, metabolite concentration etc. may be monitored and controlled as part of step 740. In one specific embodiment, a flow rate of a fluid flowing through an extracapillary space (EC) side of a bioreactor may be used in controlling the pH, oxygen concentration, carbon dioxide concentration, waste concentration, metabolite concentration etc. in the intracapillary space where the cells are expanding.
Flow 700 proceeds from step 740 to step 744 where cells are removed from the bioreactor. Step 744 may involve a number of sub-steps. For example, a harvest process 748, which itself includes a number of steps, may be performed as part of step 744. In embodiments, step 748 may involve changing circulation rates on the intracapillary space (IC) and extra capillary space (EC) sides of the bioreactor. In other embodiments, step 744 may involve circulating various materials to ensure that any cells that may have attached themselves to the inside surface of fibers are released and removed from the bioreactor. As one example, a protease may be added to break down proteins, such as glycoproteins that may aid in binding of the cells to the fibers.
In one embodiment, as part of a harvest process 748, fluid within the bioreactor (e.g., intracapillary space) may be circulated at a relatively high rate. The circulation of the fluid may promote suspension of the cell expanded at step 728. The circulation may occur for a predetermined period of time to ensure that the expanded cells are suspended in the fluid and as many as possible may be recovered from the bioreactor. Flow 700 ends at step 752.
Flow 800 may be performed in embodiments to grow cells, such as CD34+ cells in co-culture. In embodiments, the co-culture may improve growth of the CD34+ cells. Flow 800 starts at step 804 and proceeds to step 808 where first cells (e.g., human mesenchymal stem cells (hMSC's)) may be introduced into a bioreactor. In embodiments, the bioreactor (e.g., bioreactor 100 (
In embodiments, hollow fibers in the hollow fiber bioreactor may be conditioned prior to step 808. For example, in order to allow the hMSC's to adhere to the interior wall of the hollow fibers, the hollow fibers may be coated with for example a glycoproteins (fibronectin, collagen). The coating process may involve a number of substeps.
The cells introduced at step 808 may be introduced into the intracapillary space, e.g., in the interior of the hollow fibers, of the hollow fiber bioreactor. Step 808 may involve the use of a processor (1100, (
In other embodiments, step 808 may introduce the cells into an extracapillary space, e.g., on the outside of the hollow fibers, of the hollow fiber bioreactor. Step 808 may involve the use of a processor (1100, (
Flow passes from step 808 to step 812, where the first cells are exposed to first growth conditions. The first growth conditions may be optimized for growing the first cells introduced at step 808. For example, step 812 may involve feeding the first cells with a first growth media (optional step 816) that includes nutrients for growing the first cells. The growth media may include one or more of various nutrients, including glucose, phosphates, salts, etc.
After a predetermined period of time (which may depend on a certain number of the first cells having been grown within the bioreactor), flow 800 passes to 820 where second cells (e.g., HSC's, hematopoietic progenitor cells (CD34+), etc.) may be introduced into the bioreactor. In embodiments, the second cells are introduced into an intracapillary space just like the first cells. In other embodiments, as noted above, the first cells may be in the extracapillary space, while the second cells may be introduced into the intracapillary space.
In some embodiments, prior to introducing second cells, a washout procedure may be performed to remove the previous fluid from the bioreactor. As may be appreciated, the fluid in the bioreactor may include nutrient tailored for growing the first cells. Embodiments may provide for flushing this fluid out of the bioreactor prior to, or as part of step 820, and introducing the second cells in to the bioreactor.
Step 820 may involve the use of a processor (1100, (
Flow passes from step 820 to step 824, where the second cells are exposed to second growth conditions. The second growth conditions may be optimized for growing the second cells introduced at step 820. For example, step 820 may involve feeding the second cells with a second growth media (at optional step 828) that includes nutrients for growing the second cells. The second media may include one or more of various nutrients, including glucose, phosphates, salts, etc.
Additionally, in some embodiments, step 820 may involve the optional step of 832 adding growth factors that promote growth of the second cells, e.g., CD34+ cells. In embodiments, the growth factors, e.g., cytokines, may be added to promote the proliferation of cells. As one example, when growing CD34+ cells, the growth factor(s) may include one or more of: recombinant human Flt3 ligand (rhFlt-3L), recombinant human stem cell factor (rhSCF), recombinant human thrombopoietin (rhTPO), recombinant human (rh) Glial-derived neurotrophic factors, and combinations thereof. This is merely one example and in other embodiments, different growth factors, combination of growth factors, or other proteins may be used. In embodiments, the growth factors may be added to the intracapillary space of the hollow fiber bioreactor.
In embodiments, at least a portion of the growth factors may be introduced with the cells at step 820. For example, the media in which the cells are in when introduced into the bioreactor may be conditioned with a combination of growth factors including one or more of recombinant human Flt3 ligand (rhFlt-3L), recombinant human stem cell factor (rhSCF), recombinant human thrombopoietin (rhTPO), recombinant human (rh) Glial-derived neurotrophic factors, and combinations thereof. In these embodiments, step 820, and optional step 832, may involve supplementing growth factors that may have already been added to the bioreactor with the cells.
Flow passes from step 824 to step 836, where cells are expanded in co-culture. Step 836 may involve a number of optional sub-steps. For example, the cells may be fed at optional sub-step 840. Additional glucose or other nutrients may be provided to the cells as they expand in co-culture. At sub-step 844, other conditions may be controlled to expand the cells. For example, temperature, pH, gas concentrations, etc. may be monitored and changed in order to control the environment for expansion of the cells.
Flow 800 proceeds from step 836 to step 848 where cells are removed from the bioreactor. Step 848 may involve a number of sub-steps. For example, a harvest process 852, which itself includes a number of steps, may be performed as part of step 848. In embodiments, step 848 may involve changing circulation rates on the intracapillary space (IC) and extra capillary space (EC) sides of the bioreactor. In other embodiments, step 848 may involve circulating various materials to ensure that any cells that may have attached themselves to the inside surface of fibers are released and removed from the bioreactor. As one example, a protease may be added to break down proteins, such as glycoproteins (fibronectin, collagen) that may aid in binding of the cells to the fibers.
In one embodiment, as part of a harvest process 852, fluid within the bioreactor (e.g., intracapillary space) may be circulated at a relatively high rate. The circulation of the fluid may promote suspension of the cell expanded at step 836. The circulation may occur for a predetermined period of time to ensure that the expanded cells are suspended in the fluid and as many as possible may be recovered from the bioreactor. Flow 800 ends at step 856.
Flow 900 starts at step 904 and proceeds to step 908 where first cells (e.g., human mesenchymal stem cells (hMSC's)) may be grown in a static growth chamber. Step 908 may involve use of a flask or a gas permeable reactor, where fluid is not moved by pumps. Rather, the growth chamber remains stationary and fluid does not flow after being added to the chamber.
Flow 900 may then pass from step 908 to step 912 where second cells are grown statically in the static growth chamber. In embodiments, the second cells may be hematopoietic progenitor cells (e.g., CD34+ cells). After step 912, the second cells, which may have been expanded in the static growth chamber, may be removed from the growth chamber, for additional expansion in a dynamic cell expansion system (e.g., CES's 500 and/or 600) where fluid may be circulated (e.g., automatically) as the cells are expanded.
Flow 900 may then pass to step 920, where first cells (e.g., hMSC's) may be introduced into a hollow fiber bioreactor that includes a number of hollow fibers. The cells introduced at step 920 may be introduced into the interior (lumen) of the hollow fibers.
In embodiments, hollow fibers in the hollow fiber bioreactor may be conditioned prior to step 920. For example, in order to allow the hMSC's to adhere to the interior wall of the hollow fibers, the hollow fibers may be coated with for example a glycoproteins (fibronectin, collagen). The coating process may involve a number of substeps.
Step 920 may involve the use of a processor (1100, (
Step 920 may involve a number of sub-steps. In embodiments, as part of introducing cells into the hollow fiber bioreactor, the bioreactor may be rotated at sub-step 922. For example, in order to have the first cells attach to as much of the interior (lumen) of the hollow fibers as possible, the bioreactor may be rotated in a specific pattern.
The pump may then be stopped, which results in the first cells settling, and after a period of time, attaching onto a portion of the inside 1012 of the hollow fiber, as shown in
After the first cells 1008 have settled and attached, the bioreactor (and consequently fiber 1000) may be rotated 180 degrees. Examples of methods for rotating a bioreactor when loading cells, in order to distribute cells more evenly on the inside surface of hollow fibers, is described in at least U.S. Pat. No. 9,617,506, issued Apr. 11, 2017, entitled “EXPANDING CELLS IN A BIOREACTOR,” which is hereby incorporated by reference in its entirety as if set forth herein in full.
In some embodiments, after the rotation, the pump may be activated again to circulate the remaining, unattached, first cells 1008 in the intracapillary space of the hollow fiber membrane. In other embodiments, the pump may not be reactivated.
As shown in
Referring again to
After a predetermined period of time (which may depend on a certain number of the first cells having been grown within the bioreactor), flow 900 passes to 932 where second cells (e.g., HSC's, hematopoietic progenitor cells (CD34+) etc.) may be introduced into the bioreactor. In embodiments, the second cells are introduced into an intracapillary space just like the first cells. In other embodiments, as noted above, the first cells may be in the extracapillary space, while the second cells may be introduced into the intracapillary space.
In some embodiments, prior to introducing second cells, a washout procedure may be performed to remove the previous fluid from the bioreactor. As may be appreciated, the fluid in the bioreactor may include nutrient tailored for growing the first cells. Embodiments may provide for flushing this fluid out of the bioreactor prior to, or as part of step 932, and introducing the second cells in to the bioreactor.
Step 932 may involve the use of a processor (1100, (
Flow passes from step 932 to step 936, where the second cells are exposed to second growth conditions. The second growth conditions may be optimized for growing the second cells introduced at step 932. For example, step 936 may involve feeding the second cells with a second growth media (at optional step 940) that includes nutrients for growing the second cells. The second media may include one or more of various nutrients, including glucose, phosphates, salts, etc.
Additionally, in some embodiments, step 936 may involve the step 944 of adding growth factors that promote growth of the second cells, e.g., CD34+ cells. In embodiments, the growth factors, e.g., cytokines, may be added to promote the proliferation of cells. As one example, when growing CD34+ cells, the growth factor(s) may include one or more of: recombinant human Flt3 ligand (rhFlt-3L), recombinant human stem cell factor (rhSCF), recombinant human thrombopoietin (rhTPO), recombinant human (rh) Glial-derived neurotrophic factors, and combinations thereof. This is merely one example and in other embodiments, different growth factors, combination of growth factors, or other proteins may be used. In embodiments, the growth factors may be added to the intracapillary space of the hollow fiber bioreactor.
In one embodiment, at least a portion of the growth factors may be introduced with the cells at step 936. For example, the media in which the cells are in when introduced into the bioreactor may be conditioned with a combination of growth factors including one or more of recombinant human Flt3 ligand (rhFlt-3L), recombinant human stem cell factor (rhSCF), recombinant human thrombopoietin (rhTPO), recombinant human (rh) Glial-derived neurotrophic factors, and combinations thereof. In these embodiments, step 936, and optional step 944, may involve supplementing growth factors that may have already been added to the bioreactor with the cells.
Flow passes from step 936 to step 948, where cells are expanded in co-culture. Step 948 may involve a number of optional sub-steps. For example, the cells may be fed at optional sub-step 952. Additional glucose or other nutrients may be provided to the cells as they expand in co-culture. At sub-step 956, other conditions may be controlled to expand the cells. For example, temperature, pH, gas concentrations, etc. may be monitored and changed in order to control the environment for expansion of the cells.
Flow 900 proceeds from step 948 to step 960 where cells are removed from the bioreactor. Step 960 may involve a number of sub-steps. For example, a harvest process 964, which itself includes a number of steps, may be performed as part of step 960. In embodiments, step 964 may involve changing circulation rates on the intracapillary space (IC) and extra capillary space (EC) sides of the bioreactor. In other embodiments, step 964 may involve circulating various materials to ensure that any cells that may have attached themselves to the inside surface of fibers are released and removed from the bioreactor. As one example, a protease may be added to break down proteins, such as glycoproteins that may aid in binding of the cells to the fibers.
In one embodiment, as part of a harvest process 964, fluid within the bioreactor (e.g., intracapillary space) may be circulated at a relatively high rate. The circulation of the fluid may promote suspension of the cell expanded at step 948. The circulation may occur for a predetermined period of time to ensure that the expanded cells are suspended in the fluid and as many as possible may be recovered from the bioreactor. Flow 900 ends at step 968.
With respect to flows 700, 800, and 900 illustrated in
Also, it is noted that although flows 700, 800, and 900 have been described above with various steps in particular order, the present invention is not limited thereto. In other embodiments, the various steps and sub-steps may be performed in a different order, in parallel, partially in the order shown in
The computing system 1100 may include a user interface 1102, a processing system 1104, and/or storage 1106. The user interface 1102 may include output device(s) 1108, and/or input device(s) 1110 as understood by a person of skill in the art. Output device(s) 1108 may include one or more touch screens, in which the touch screen may comprise a display area for providing one or more application windows. The touch screen may also be an input device 1110 that may receive and/or capture physical touch events from a user or operator, for example. The touch screen may comprise a liquid crystal display (LCD) having a capacitance structure that allows the processing system 1104 to deduce the location(s) of touch event(s), as understood by those of skill in the art. The processing system 1104 may then map the location of touch events to user interface (UI) elements rendered in predetermined locations of an application window. The touch screen may also receive touch events through one or more other electronic structures, according to embodiments. Other output devices 1108 may include a printer, speaker, etc. Other input devices 1110 may include a keyboard, other touch input devices, mouse, voice input device, etc., as understood by a person of skill in the art.
Processing system 1104 may include a processing unit 1112 and/or a memory 1114, according to embodiments of the present disclosure. The processing unit 1112 may be a general purpose processor operable to execute instructions stored in memory 1114. Processing unit 1112 may include a single processor or multiple processors, according to embodiments. Further, in embodiments, each processor may be a multi-core processor having one or more cores to read and execute separate instructions. The processors may include general purpose processors, application specific integrated circuits (ASICs), field programmable gate arrays (FPGAs), other integrated circuits, etc., as understood by a person of skill in the art.
The memory 1114 may include any short-term or long-term storage for data and/or processor executable instructions, according to embodiments. The memory 1114 may include, for example, Random Access Memory (RAM), Read-Only Memory (ROM), or Electrically Erasable Programmable Read-Only Memory (EEPROM), as understood by a person of skill in the art. Other storage media may include, for example, CD-ROM, tape, digital versatile disks (DVD) or other optical storage, tape, magnetic disk storage, magnetic tape, other magnetic storage devices, etc., as understood by a person of skill in the art.
Storage 1106 may be any long-term data storage device or component. Storage 1106 may include one or more of the systems described in conjunction with the memory 1114, according to embodiments. The storage 1106 may be permanent or removable. In embodiments, storage 806 stores data generated or provided by the processing system 104.
Some examples that may implement aspects of the embodiments are provided below. Although specific features may be described in these examples, they are provided merely for illustrative and descriptive purposes. The present invention is not limited to the examples provided below.
Initial expansion of unselected cord blood-derived (CB) HSCs, CD34+ cells from three (3) donors are acquired from AllCells® (Alameda, CA) by positive immunomagnetic selection of cord blood and grown in co-culture with bone marrow-derived hMSCs under static conditions (5% CO2 & 37.0° C.) with serum-free CellGenix (Freiburg, Germany) CellGro® GMP SCGM with the addition of StemCell2MAX™ supplement (rhFlt-3L, rhSCF, rhTPO, rhGlial-derived neurotrophic factors) at a 1:100 concentration to develop the inoculum for a hollow fiber cell expansion system, e.g., the Quantum® Cell Expansion System (CES). Each of the Quantum CES bioreactors is coated with five (5) mg of human fibronectin overnight and seeded with unmatched hMSCs at 3.0×103/cm2 five (5) days in advance of HSC introduction. The bioreactors are seeded with CB-derived CD34+ cells in CelIGro® GMP SCGM+StemCell2MAX at a cell density of 3.0×104/mL for a total seeding of 5.7×106 cells and subsequently expanded for 6.6 days using a mixed gas (5% CO2, 20% O2, balance N2) at 37.0° C. in co-culture. Cells are seeded to the bioreactor, expanded, and harvested using automated tasks on the Quantum® CES. Specifically, cells are grown in the intracapillary loop of the bioreactor and base media additions are made through the extracapillary loop of the system in order to enhance hMSC-CB CD34+ cell interactions. Metabolites are quantified daily with Abbott i-STAT® analyzers. Cells are counted with a Beckman Coulter Vi-CELL™ XR Cell Viability Analyzer using a diameter size range of 5-50 μm. Harvested cells are stained for surface biomarkers with BD Mouse Anti-Human CD34-FITC, BD Mouse Anti-Human CD34-PE, BD Mouse Anti-Human CD38-APC, MB CD133/1-PE, and eBioscience Fixable Viability Dye eFluor® 780 and analyzed by flow cytometry using a BD FACSCanto II equipped with BD FACSDiva software. Fluorescent microscopy images are captured with a Zeiss Axio Observer A1 microscope equipped with ZEN pro software. The Stem Cell Technologies Human CFU Methocult™ Assay is used to induce the differentiation of harvested CB-derived CD34+ cells.
The results may suggest that the Quantum CES hollow fiber membrane bioreactor can support the expansion of CB-derived CD34+, CD38-CD133+ progenitor cells in co-culture using an automated CES. The growth factor supplement of rhFlt-3L, rhSCF, rhTPO, rhGlial-derived neurotrophic factors may support the co-culture of CB-derived CD34+ lineage cells. Expanded CB-derived CD34+ cells may demonstrate lineage differentiation in the presence of appropriate cytokines and supplements (SCF, GM-CSF, IL-3, GSF, EPO). Table 2 below provides a summary of flow cytometry results.
The culture of I-Mag selected human HSC CB CD34+ cells (frozen CB008F-2) obtained from AllCells using IMDM media supplemented with FBS or human AB serum in mono- or co-culture with human mesenchymal stem cells (hMSCs) to improve the media cost framework of CD34+ expansion is explored. Cell culture devices include the Wilson G-Rex 10 Gas Permaeable Membrane devices and conventional tissue culture polystyrene flasks. After the results of the first experiment, a decision is made to switch to a StemSpan SPEM II media containing modified IMDM (BSA, rh-insulin, transferrin) plus FBS or Human Serum AB as well as to increase the cell seeding density in order to improve cell growth and biomarker expression.
Experiment 1
T25 TCPS Flasks are seeded with hMSC-P2T1 at 1,000 cells/cm2 in Gibco alpha-MEM (Cat. No. 32561-037) Complete Medium (CM224), incubated at 37° C. (5% CO2), and grown to 80% confluency on Day-6 prior to seeding with thawed CB CD34+ cells. By comparison, no hMSCs are seeded into the Wilson G-Rex gas permeable cell culture device. CB CD34+ cells are seeded at a concentration of 2.0×104/mL and grown with 7 mL of Gibco IMDM (Cat. No. 31980-030), 20% HyClone FBS (Cat. No. 5H30070.03) or 18% Akron HS-AB (Cat. No. AK9340-0100), plus Gibco Penicillin/Streptomycin/Neomycin antibiotics (Cat. No. 15640-055) for four (4) days. The CD34+ cell seeding density is based on a recommendation to maintain the cell concentration below 3.0×104/mL. Culture vessels are weighed to determine culture volumes and cell counts are captured with a calibrated Beckman Coulter Vi-Cell XR Cell Viability Analyzer on Days 0, 2, and 4.
Experiment 2
Six (6) T25 TCPS Flasks are seeded with hMSC-P2T1 at 8.48×103/cm2 in Gibco alpha-MEM Complete Medium (CM231), incubated at 37° C. (5% CO2), and grown to 80% confluency on Day-3 prior to seeding with thawed (37° C.) CB CD34+ cells (AllCells CB-CD34+, Cat. No. CB008F-2, ID No. CBP140129C). CB CD34+ cells (2.5 mL) are resuspended in 22.5 mL of StemSpan SFEM II media, centrifuged at 500xg for 7 minutes, resuspended in 10 mL of respective complete media, and counted with a calibrated Beckman Coulter Vi-Cell NR Cell Viability Analyzer. Each flask media is exchanged with 6 mL of sterile filtered (Corning 0.22 μm PES) StemSpan SFEM II Complete Media 20% FBS (HyClone Cat. No. 5H30070.03) or 20% HS-AB (Innovative Research (Cat. IPLA-SERAB-OTC-16138), Gibco Pennicillin/Streptomycin/Neomycin Antibiotics (Cat. No. 15640-055). A total of four (4) T25 co-culture flasks are seeded with CB CD34+ cells at 3.00×104/mL or 3.00×105/mL into 6 mL per flask with StemSpan SFEM II media supplemented with either 20% FBS or 20% HS-AB, incubated at 37° C. (5% CO2) for four (4) days. Suspension cells from each flask are removed on Day-2, transferred to a 15 mL sterile centrifuge tube, centrifuged at 500xg for 7 minutes, resuspended in 6 mL of their respective Complete StemSpan SFEM II media, and returned to T25 co-culture flasks for incubation. On Day-4, images of suspension cells are captured by phase-contrast photomicroscopy (Olympus CKX41 with QCapture Pro 6.0 software), flasks are weighed to determine flask volume, and cells are counted as previously described. Aliquots (1.25×105 cells) of the high cell seeding density are prepared for flow cytometry staining (BD Pharmingen FITC Mouse Anti-human CD34 Cat. 555821, BD Pharmingen FITC Mouse IgG1K isotype control Cat. 555748, BD Pharmingen APC Mouse Anti-human CD38 Cat. 555462, BD Pharmingen Mouse IgG1K Isotype Control Cat. 555751, BD Pharmingen PE Mouse Anti-human CD34 Cat. 555822, BD Pharmingen PE Mouse IgG1K Isotype Control Cat. 555749, Miltenyi Biotec CD133/1-PE Cat. 180-080-801) using a modified version of the Flow Cytometry Prep Protocol. Flow data are acquired and analyzed without fixative using a BD FACSCanto® II flow cytometer equipped with BD FACSDiva® v6.1.3 software.
Experiment 1 may evaluate the mono- and co-culture of cord blood derived CD34+ cells at the low seeding density of 2.00×104/mL in a total volume of 7 mL using IMDM base media supplemented with 20% FBS or 18% HS. T25 tissue culture polystyrene (TCPS) flasks and gas permeable G-Rex-10 vessels are used as the primary static culture environment.
Both the FBS and HS supplemented IMDM demonstrate an increase in cell count by Day-2. However, there is also a decrease in cell concentration by Day-4. There is also reduction in cell membrane integrity from Day-2 to Day-4 in both of the supplemented media from 87% to 76.4% with FBS and from 88.5% to 76.3% with HS. In our case, this may be due to the lack of a media change on Day-3 or the low cell seeding density of 2.00×105/mL. In summary, the 20% FBS supplemented media may generate a 7.5-7.6 fold-increase in flask co-culture, 7.1 fold-increase in flask mono-culture, and a 7.0-7.2 fold-increase in the G-Rex-10 mono-culture by Day-4. By comparison, the 18% HS supplemented media may generate a 7.3-7.5 fold-increase in flask co-culture, 6.8 fold-increase in flask mono-culture, and a 6.7-6.9 fold-increase in the G-Rex10 mono-culture by Day-4.
Experiment 2 may evaluate both low and high seeding densities.
Below is an example of a protocol that may be used in embodiments. The protocol indicates possible modification from a conventional protocol(s) utilized when using a cell expansion system (CES).
CES Cell Load Modification 3—Load with Circ. Distribution & Rotation
A conventional Pre-selected MSC Expansion Protocol, may be performed with the following modifications shown in combined bold, underline, and italics below. Rotate the bioreactors 180 degrees and allow the cells to settle to the top of the hollow fiber membrane (HFM) for 5 minutes. Then rotate the bioreactor back to the “home” horizontal position and proceed with the expansion protocol. The rationale for the modification is to distribute the cells over the entire surface area of the bioreactor hollow fiber (
Day 0: Attach Feeder Cells with Rotation
Purpose: enables adherent cells to attach to the bioreactor membrane while allowing flow on the EC circulation loop. The pump flow rate to the IC loop is set to zero.
Prior to loading the cells into all a CES with Distribution and Rotation, install a Custom Task using the following existing/modified steps: Config>Task via the touch screen display or GUI. These solutions and corresponding volumes are based on the either default or modified settings for these custom tasks.
Return to conventional cell feeding tasks on Day 2 or as needed and continue with the pre-cultured hMSC expansion protocol using Feed Cells Task.
Day 5: Introduce CB CD34+Suspension Cells with Rotation
IC/EC Exchange & Condition Media for CB CD34+ Cells.
Attach SCGM Base Media to IC Media line. Perform IC/EC Washout and Condition Media Tasks respectively.
Attach Cell Inlet bag with CB CD34+ cell suspension of SCGM (98 mL)+StemCell2MAX 100X supplement (2 mL) to Cell Inlet line of the System with a sterile welder.
Resuspension of Cells Prior to Harvest
The purpose of this Circulation Task is to resuspend those cells that may be attached to the hMSC feeder layer during co-culture prior to initiating the Harvest Task.
Harvest
CES Harvest Task with Modification.
It will be apparent to those skilled in the art that various modifications and variations can be made to the methods and structure of the present invention without departing from its scope. Thus it should be understood that the present invention is not be limited to the specific examples given. Rather, the present invention is intended to cover modifications and variations within the scope of the following claims and their equivalents.
While example embodiments and applications of the present invention have been illustrated and described, it is to be understood that the invention is not limited to the precise configuration and resources described above. Various modifications, changes, and variations apparent to those skilled in the art may be made in the arrangement, operation, and details of the methods and systems of the present invention disclosed herein without departing from the scope of the present invention.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2017/034544 | 5/25/2017 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2017/205667 | 11/30/2017 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
2997077 | Rodrigues | Aug 1961 | A |
3013435 | Rodrigues | Dec 1961 | A |
3067915 | Shapiro et al. | Dec 1962 | A |
3191807 | Rodrigues | Jun 1965 | A |
3283727 | Rodrigues | Nov 1966 | A |
3701717 | Ingvorsen | Oct 1972 | A |
3821087 | Knazek et al. | Jun 1974 | A |
3896061 | Tanzawa et al. | Jul 1975 | A |
4173415 | Wyatt | Nov 1979 | A |
4301010 | Eddleman et al. | Nov 1981 | A |
4301118 | Eddleman et al. | Nov 1981 | A |
4391912 | Yoshida et al. | Jul 1983 | A |
4412990 | Lundblad et al. | Nov 1983 | A |
4418691 | Yannas et al. | Dec 1983 | A |
4439322 | Sonoda et al. | Mar 1984 | A |
4439901 | Eddleman | Apr 1984 | A |
4440853 | Michaels et al. | Apr 1984 | A |
4478829 | Landaburu et al. | Oct 1984 | A |
4486188 | Altshuler et al. | Dec 1984 | A |
4509695 | Bessman | Apr 1985 | A |
4585654 | Landaburu et al. | Apr 1986 | A |
4618586 | Walker et al. | Oct 1986 | A |
4629686 | Gruenberg | Dec 1986 | A |
4647539 | Bach | Mar 1987 | A |
4650766 | Harm et al. | Mar 1987 | A |
4670544 | Schwinn et al. | Jun 1987 | A |
4722902 | Harm et al. | Feb 1988 | A |
4727059 | Binder et al. | Feb 1988 | A |
4789658 | Yoshimoto et al. | Dec 1988 | A |
4804628 | Cracauer et al. | Feb 1989 | A |
4828706 | Eddleman | May 1989 | A |
4885087 | Kopf | Dec 1989 | A |
4889812 | Guinn et al. | Dec 1989 | A |
4894342 | Guinn et al. | Jan 1990 | A |
4897358 | Carrasco | Jan 1990 | A |
4910139 | Chang et al. | Mar 1990 | A |
4918019 | Guinn | Apr 1990 | A |
4960521 | Keller | Oct 1990 | A |
4973558 | Wilson et al. | Nov 1990 | A |
4988623 | Schwarz et al. | Jan 1991 | A |
5015585 | Robinson | May 1991 | A |
5019054 | Clement et al. | May 1991 | A |
5079168 | Amiot | Jan 1992 | A |
5081035 | Halberstadt | Jan 1992 | A |
5126238 | Gebhard et al. | Jun 1992 | A |
5130141 | Law et al. | Jul 1992 | A |
5149544 | Gentile et al. | Sep 1992 | A |
5156844 | Aebischer et al. | Oct 1992 | A |
5162225 | Sager et al. | Nov 1992 | A |
5169930 | Ruoslahti et al. | Dec 1992 | A |
5192553 | Boyse et al. | Mar 1993 | A |
5197985 | Caplan et al. | Mar 1993 | A |
5202254 | Amiot et al. | Apr 1993 | A |
5225346 | Matsumiya et al. | Jul 1993 | A |
5226914 | Caplan et al. | Jul 1993 | A |
5240614 | Ofsthun et al. | Aug 1993 | A |
5240861 | Bieri | Aug 1993 | A |
5252216 | Folena-Wasserman et al. | Oct 1993 | A |
5283058 | Faustman | Feb 1994 | A |
5310676 | Johansson et al. | May 1994 | A |
5324428 | Flaherty | Jun 1994 | A |
5330915 | Wilson et al. | Jul 1994 | A |
5342752 | Platz et al. | Aug 1994 | A |
5399493 | Emerson et al. | Mar 1995 | A |
5416022 | Amiot | May 1995 | A |
5422197 | Zito | Jun 1995 | A |
5436151 | McGlave et al. | Jul 1995 | A |
5437994 | Emerson et al. | Aug 1995 | A |
5439757 | Zito | Aug 1995 | A |
5459069 | Palsson et al. | Oct 1995 | A |
5460964 | McGlave et al. | Oct 1995 | A |
H1509 | Eran et al. | Dec 1995 | H |
5478739 | Slivka et al. | Dec 1995 | A |
5486359 | Caplan et al. | Jan 1996 | A |
5496659 | Zito | Mar 1996 | A |
5507949 | Ho | Apr 1996 | A |
5510257 | Sirkar et al. | Apr 1996 | A |
5512180 | Ho | Apr 1996 | A |
5527467 | Ofsthun et al. | Jun 1996 | A |
5541105 | Melink et al. | Jul 1996 | A |
5543316 | Zawadzka et al. | Aug 1996 | A |
5545492 | Zito | Aug 1996 | A |
5549674 | Humes et al. | Aug 1996 | A |
5571720 | Grandics et al. | Nov 1996 | A |
5581687 | Lyle et al. | Dec 1996 | A |
5591625 | Gerson et al. | Jan 1997 | A |
5593580 | Kopf | Jan 1997 | A |
5595909 | Hu et al. | Jan 1997 | A |
5599703 | Davis et al. | Feb 1997 | A |
5605822 | Emerson et al. | Feb 1997 | A |
5605829 | McGlave et al. | Feb 1997 | A |
5605835 | Hu et al. | Feb 1997 | A |
5622857 | Goffe | Apr 1997 | A |
5626731 | Cooley et al. | May 1997 | A |
5627070 | Gruenberg | May 1997 | A |
5631006 | Melink et al. | May 1997 | A |
5635386 | Palsson et al. | Jun 1997 | A |
5635387 | Fei et al. | Jun 1997 | A |
5643736 | Bruder et al. | Jul 1997 | A |
5646043 | Emerson et al. | Jul 1997 | A |
5653887 | Wahl et al. | Aug 1997 | A |
5654186 | Cerami et al. | Aug 1997 | A |
5656421 | Gebhard et al. | Aug 1997 | A |
5658995 | Kohn et al. | Aug 1997 | A |
5667985 | O'Leary et al. | Sep 1997 | A |
5670147 | Emerson et al. | Sep 1997 | A |
5670351 | Emerson et al. | Sep 1997 | A |
5674750 | Kraus et al. | Oct 1997 | A |
5684712 | Goffe et al. | Nov 1997 | A |
5686289 | Humes et al. | Nov 1997 | A |
5688687 | Palsson et al. | Nov 1997 | A |
5695989 | Kalamasz | Dec 1997 | A |
5700289 | Breitbart et al. | Dec 1997 | A |
5705534 | D'Agostino et al. | Jan 1998 | A |
5707859 | Miller et al. | Jan 1998 | A |
5712163 | Parenteau et al. | Jan 1998 | A |
5728581 | Schwartz et al. | Mar 1998 | A |
5733541 | Taichman et al. | Mar 1998 | A |
5733542 | Haynesworth et al. | Mar 1998 | A |
5736396 | Bruder et al. | Apr 1998 | A |
5744347 | Wagner et al. | Apr 1998 | A |
5750651 | Oppermann et al. | May 1998 | A |
5753506 | Johe | May 1998 | A |
5763194 | Slowiaczek et al. | Jun 1998 | A |
5763197 | Tsukamoto et al. | Jun 1998 | A |
5763261 | Gruenberg | Jun 1998 | A |
5763266 | Palsson et al. | Jun 1998 | A |
5766944 | Ruiz | Jun 1998 | A |
5772994 | Ildstad et al. | Jun 1998 | A |
5783075 | Eddleman et al. | Jul 1998 | A |
5783216 | Faustman | Jul 1998 | A |
5785912 | Cooley et al. | Jul 1998 | A |
5804446 | Cerami et al. | Sep 1998 | A |
5806529 | Reisner et al. | Sep 1998 | A |
5807686 | Wagner et al. | Sep 1998 | A |
5811094 | Caplan et al. | Sep 1998 | A |
5811397 | Francavilla et al. | Sep 1998 | A |
5817773 | Wilson et al. | Oct 1998 | A |
5821218 | Toback et al. | Oct 1998 | A |
5827735 | Young et al. | Oct 1998 | A |
5827740 | Pittenger | Oct 1998 | A |
5830921 | Cooley et al. | Nov 1998 | A |
5833979 | Schinstine et al. | Nov 1998 | A |
5837258 | Grotendorst | Nov 1998 | A |
5837539 | Caplan et al. | Nov 1998 | A |
5840502 | Van Vlasselaer | Nov 1998 | A |
5840576 | Schinstine et al. | Nov 1998 | A |
5840580 | Terstappen et al. | Nov 1998 | A |
5842477 | Naughton et al. | Dec 1998 | A |
5843633 | Yin et al. | Dec 1998 | A |
5846796 | Cerami et al. | Dec 1998 | A |
5853247 | Shroyer | Dec 1998 | A |
5853717 | Schinstine et al. | Dec 1998 | A |
5855608 | Brekke et al. | Jan 1999 | A |
5855613 | Antanavich et al. | Jan 1999 | A |
5855619 | Caplan et al. | Jan 1999 | A |
5858747 | Schinstine et al. | Jan 1999 | A |
5858782 | Long et al. | Jan 1999 | A |
5861315 | Nakahata | Jan 1999 | A |
5866115 | Kanz et al. | Feb 1999 | A |
5866420 | Talbot et al. | Feb 1999 | A |
5868930 | Kopf | Feb 1999 | A |
5882295 | Kope | Mar 1999 | A |
5882918 | Goffe | Mar 1999 | A |
5882929 | Fofonoff et al. | Mar 1999 | A |
5888807 | Palsson et al. | Mar 1999 | A |
5902741 | Purchio et al. | May 1999 | A |
5906827 | Khouri et al. | May 1999 | A |
5906934 | Grande et al. | May 1999 | A |
5908782 | Marshak et al. | Jun 1999 | A |
5908784 | Johnstone et al. | Jun 1999 | A |
5912177 | Turner et al. | Jun 1999 | A |
5914108 | Tsukamoto et al. | Jun 1999 | A |
5922597 | Verfaillie et al. | Jul 1999 | A |
5922847 | Broudy et al. | Jul 1999 | A |
5925567 | Kraus et al. | Jul 1999 | A |
5928945 | Seliktar et al. | Jul 1999 | A |
5935849 | Schinstine et al. | Aug 1999 | A |
5938929 | Shimagaki et al. | Aug 1999 | A |
5939323 | Valentini et al. | Aug 1999 | A |
5942225 | Bruder et al. | Aug 1999 | A |
5955353 | Amiot | Sep 1999 | A |
5958763 | Goffe | Sep 1999 | A |
5965436 | Thiede et al. | Oct 1999 | A |
5972703 | Long et al. | Oct 1999 | A |
5980795 | Klotzer et al. | Nov 1999 | A |
5981211 | Hu et al. | Nov 1999 | A |
5981708 | Lawman et al. | Nov 1999 | A |
5985653 | Armstrong et al. | Nov 1999 | A |
5994129 | Armstrong et al. | Nov 1999 | A |
5998184 | Shi | Dec 1999 | A |
6001585 | Gramer | Dec 1999 | A |
6001643 | Spaulding | Dec 1999 | A |
6001647 | Peck et al. | Dec 1999 | A |
6004743 | Kenyon et al. | Dec 1999 | A |
6010696 | Caplan et al. | Jan 2000 | A |
6015554 | Galy | Jan 2000 | A |
6022540 | Bruder et al. | Feb 2000 | A |
6022742 | Kopf | Feb 2000 | A |
6022743 | Naughton et al. | Feb 2000 | A |
6027743 | Khouri et al. | Feb 2000 | A |
6029101 | Yoshida et al. | Feb 2000 | A |
6030836 | Thiede et al. | Feb 2000 | A |
6040180 | Johe | Mar 2000 | A |
6045818 | Cima et al. | Apr 2000 | A |
6048721 | Armstrong et al. | Apr 2000 | A |
6048727 | Kopf | Apr 2000 | A |
6049026 | Muschler | Apr 2000 | A |
6054121 | Cerami et al. | Apr 2000 | A |
6060270 | Humes | May 2000 | A |
6066317 | Yang et al. | May 2000 | A |
6071691 | Hoekstra et al. | Jun 2000 | A |
6074366 | Rogers et al. | Jun 2000 | A |
6077708 | Collins et al. | Jun 2000 | A |
6082364 | Balian et al. | Jul 2000 | A |
6083747 | Wong et al. | Jul 2000 | A |
6086643 | Clark et al. | Jul 2000 | A |
6087113 | Caplan et al. | Jul 2000 | A |
6096532 | Armstrong et al. | Aug 2000 | A |
6096537 | Chappel | Aug 2000 | A |
6103117 | Shimagaki et al. | Aug 2000 | A |
6103522 | Torok-Storb et al. | Aug 2000 | A |
6110176 | Shapira | Aug 2000 | A |
6110482 | Khouri et al. | Aug 2000 | A |
6114307 | Jaspers et al. | Sep 2000 | A |
6117985 | Thomas et al. | Sep 2000 | A |
6120491 | Kohn et al. | Sep 2000 | A |
6127141 | Kopf | Oct 2000 | A |
6129911 | Faris | Oct 2000 | A |
6143293 | Weiss et al. | Nov 2000 | A |
6146360 | Rogers et al. | Nov 2000 | A |
6146888 | Smith et al. | Nov 2000 | A |
6149902 | Artavanis-Tsakonas et al. | Nov 2000 | A |
6149906 | Mosca | Nov 2000 | A |
6150164 | Humes | Nov 2000 | A |
6152964 | Van Blitterswijk et al. | Nov 2000 | A |
6162643 | Wille, Jr. | Dec 2000 | A |
6165225 | Antanavich et al. | Dec 2000 | A |
6165785 | Ogle et al. | Dec 2000 | A |
6174333 | Kadiyala et al. | Jan 2001 | B1 |
6174526 | Cerami et al. | Jan 2001 | B1 |
6174666 | Pavlakis et al. | Jan 2001 | B1 |
6179871 | Halpern | Jan 2001 | B1 |
6197325 | MacPhee et al. | Mar 2001 | B1 |
6197575 | Griffith et al. | Mar 2001 | B1 |
6200606 | Peterson et al. | Mar 2001 | B1 |
6214369 | Grande et al. | Apr 2001 | B1 |
6214574 | Kopf | Apr 2001 | B1 |
6224860 | Brown | May 2001 | B1 |
6225119 | Qasba et al. | May 2001 | B1 |
6225368 | D'Agostino et al. | May 2001 | B1 |
6228117 | De Bruijn et al. | May 2001 | B1 |
6228607 | Kersten et al. | May 2001 | B1 |
6228635 | Armstrong et al. | May 2001 | B1 |
6238908 | Armstrong et al. | May 2001 | B1 |
6239157 | Mbalaviele | May 2001 | B1 |
6242252 | Reid et al. | Jun 2001 | B1 |
6248319 | Zsebo et al. | Jun 2001 | B1 |
6248587 | Rodgers et al. | Jun 2001 | B1 |
6255112 | Thiede et al. | Jul 2001 | B1 |
6258597 | Bachovchin et al. | Jul 2001 | B1 |
6258778 | Rodgers et al. | Jul 2001 | B1 |
6261549 | Fernandez et al. | Jul 2001 | B1 |
6280718 | Kaufman et al. | Aug 2001 | B1 |
6280724 | Moore | Aug 2001 | B1 |
6281012 | McIntosh et al. | Aug 2001 | B1 |
6281195 | Rueger et al. | Aug 2001 | B1 |
6287864 | Bagnis et al. | Sep 2001 | B1 |
6291249 | Mahant et al. | Sep 2001 | B1 |
6297213 | Oppermann et al. | Oct 2001 | B1 |
6299650 | Van Blitterswijk et al. | Oct 2001 | B1 |
6306424 | Vyakarnam et al. | Oct 2001 | B1 |
6306575 | Thomas et al. | Oct 2001 | B1 |
6322784 | Pittenger et al. | Nov 2001 | B1 |
6322786 | Anderson | Nov 2001 | B1 |
6326198 | Emerson et al. | Dec 2001 | B1 |
6326201 | Fung et al. | Dec 2001 | B1 |
6328765 | Hardwick et al. | Dec 2001 | B1 |
6328960 | McIntosh et al. | Dec 2001 | B1 |
6333029 | Vyakarnam et al. | Dec 2001 | B1 |
6335195 | Rodgers et al. | Jan 2002 | B1 |
6338942 | Kraus et al. | Jan 2002 | B2 |
6340592 | Stringer | Jan 2002 | B1 |
6342370 | Connolly et al. | Jan 2002 | B1 |
6355239 | Bruder et al. | Mar 2002 | B1 |
6358252 | Shapira | Mar 2002 | B1 |
6361997 | Huss | Mar 2002 | B1 |
6365149 | Vyakarnam et al. | Apr 2002 | B2 |
6368636 | McIntosh et al. | Apr 2002 | B1 |
6372210 | Brown | Apr 2002 | B2 |
6372244 | Antanavich et al. | Apr 2002 | B1 |
6372494 | Naughton et al. | Apr 2002 | B1 |
6372892 | Ballinger et al. | Apr 2002 | B1 |
6376742 | Zdrahala et al. | Apr 2002 | B1 |
6379953 | Bruder et al. | Apr 2002 | B1 |
6387367 | Davis-Sproul et al. | May 2002 | B1 |
6387369 | Pittenger et al. | May 2002 | B1 |
6387693 | Rieser et al. | May 2002 | B2 |
6387964 | D'Agostino et al. | May 2002 | B1 |
6392118 | Hammang et al. | May 2002 | B1 |
6394812 | Sullivan et al. | May 2002 | B1 |
6399580 | Elias et al. | Jun 2002 | B1 |
6410320 | Humes | Jun 2002 | B1 |
6414219 | Denhardt et al. | Jul 2002 | B1 |
6416496 | Rogers et al. | Jul 2002 | B1 |
6417205 | Cooke et al. | Jul 2002 | B1 |
6419829 | Ho et al. | Jul 2002 | B2 |
6420138 | Gentz et al. | Jul 2002 | B1 |
6423681 | Barasch et al. | Jul 2002 | B1 |
6426332 | Rueger et al. | Jul 2002 | B1 |
6428802 | Atala | Aug 2002 | B1 |
6429012 | Kraus et al. | Aug 2002 | B1 |
6429013 | Halvorsen et al. | Aug 2002 | B1 |
6432653 | Okarma | Aug 2002 | B1 |
6432711 | Dinsmore et al. | Aug 2002 | B1 |
6440407 | Bauer et al. | Aug 2002 | B1 |
6440734 | Pykett et al. | Aug 2002 | B1 |
6451562 | Ruben et al. | Sep 2002 | B1 |
6454811 | Sherwood et al. | Sep 2002 | B1 |
6455678 | Yin et al. | Sep 2002 | B1 |
6458585 | Vachula et al. | Oct 2002 | B1 |
6458589 | Rambhatla et al. | Oct 2002 | B1 |
6461495 | Morrissey et al. | Oct 2002 | B1 |
6461853 | Zhu | Oct 2002 | B1 |
6464983 | Grotendorst | Oct 2002 | B1 |
6465205 | Hicks, Jr. | Oct 2002 | B2 |
6465247 | Weissman et al. | Oct 2002 | B1 |
6465249 | Reya et al. | Oct 2002 | B2 |
6468794 | Uchida et al. | Oct 2002 | B1 |
6472200 | Mitrani | Oct 2002 | B1 |
6475481 | Talmadge | Nov 2002 | B2 |
6479064 | Atala | Nov 2002 | B1 |
6482231 | Abatangelo et al. | Nov 2002 | B1 |
6482411 | Ahuja et al. | Nov 2002 | B1 |
6482645 | Atala | Nov 2002 | B2 |
6482926 | Thomas et al. | Nov 2002 | B1 |
6488925 | Ruben et al. | Dec 2002 | B2 |
6491918 | Thomas et al. | Dec 2002 | B1 |
6495129 | Li et al. | Dec 2002 | B1 |
6495364 | Hammang et al. | Dec 2002 | B2 |
6497875 | Sorrell et al. | Dec 2002 | B1 |
6498034 | Strobl | Dec 2002 | B1 |
6506574 | Rambhatla et al. | Jan 2003 | B1 |
6511510 | de Bruijn et al. | Jan 2003 | B1 |
6511767 | Calver et al. | Jan 2003 | B1 |
6511958 | Atkinson et al. | Jan 2003 | B1 |
6514514 | Atkinson et al. | Feb 2003 | B1 |
6524452 | Clark et al. | Feb 2003 | B1 |
6528052 | Smith et al. | Mar 2003 | B1 |
6528245 | Sanchez-Ramos et al. | Mar 2003 | B2 |
6531445 | Cohen et al. | Mar 2003 | B1 |
6534084 | Vyakarnam et al. | Mar 2003 | B1 |
6537807 | Smith et al. | Mar 2003 | B1 |
6541024 | Kadiyala et al. | Apr 2003 | B1 |
6541249 | Wager et al. | Apr 2003 | B2 |
6544506 | Reisner | Apr 2003 | B2 |
6548734 | Glimcher et al. | Apr 2003 | B1 |
6555324 | Olweus et al. | Apr 2003 | B1 |
6555374 | Gimble et al. | Apr 2003 | B1 |
6559119 | Burgess et al. | May 2003 | B1 |
6562616 | Toner et al. | May 2003 | B1 |
6565843 | Cohen et al. | May 2003 | B1 |
6566126 | Cadwell | May 2003 | B2 |
6569421 | Hodges | May 2003 | B2 |
6569427 | Boyse et al. | May 2003 | B1 |
6569428 | Isner et al. | May 2003 | B1 |
6569654 | Shastri et al. | May 2003 | B2 |
6576188 | Rose et al. | Jun 2003 | B1 |
6576428 | Assenmacher et al. | Jun 2003 | B1 |
6576464 | Gold et al. | Jun 2003 | B2 |
6576465 | Long | Jun 2003 | B1 |
6582471 | Bittmann et al. | Jun 2003 | B1 |
6582955 | Martinez et al. | Jun 2003 | B2 |
6586192 | Peschle et al. | Jul 2003 | B1 |
6589728 | Csete et al. | Jul 2003 | B2 |
6589786 | Mangano et al. | Jul 2003 | B1 |
6593123 | Wright et al. | Jul 2003 | B1 |
6596274 | Abatangelo et al. | Jul 2003 | B1 |
6599300 | Vibe-Hansen et al. | Jul 2003 | B2 |
6599520 | Scarborough et al. | Jul 2003 | B2 |
6610535 | Lu et al. | Aug 2003 | B1 |
6613798 | Porter et al. | Sep 2003 | B1 |
6616912 | Eddleman et al. | Sep 2003 | B2 |
6617070 | Morrissey et al. | Sep 2003 | B1 |
6617152 | Bryhan et al. | Sep 2003 | B2 |
6617159 | Cancedda et al. | Sep 2003 | B1 |
6623749 | Williams et al. | Sep 2003 | B2 |
6623942 | Ruben et al. | Sep 2003 | B2 |
6624108 | Clark et al. | Sep 2003 | B1 |
6626950 | Brown et al. | Sep 2003 | B2 |
6627191 | Bartelmez et al. | Sep 2003 | B1 |
6629003 | Frizzell et al. | Sep 2003 | B1 |
6632425 | Li et al. | Oct 2003 | B1 |
6632620 | Makarovskiy | Oct 2003 | B1 |
6632934 | Moreadith et al. | Oct 2003 | B1 |
6638765 | Rosenberg | Oct 2003 | B1 |
6642019 | Anderson et al. | Nov 2003 | B1 |
6642048 | Xu et al. | Nov 2003 | B2 |
6642049 | Chute et al. | Nov 2003 | B1 |
6642201 | Khavinson et al. | Nov 2003 | B1 |
6645489 | Pykett et al. | Nov 2003 | B2 |
6645727 | Thomas et al. | Nov 2003 | B2 |
6645763 | Kobayashi et al. | Nov 2003 | B2 |
6649189 | Talmadge et al. | Nov 2003 | B2 |
6649595 | Clackson et al. | Nov 2003 | B2 |
6649631 | Orme et al. | Nov 2003 | B1 |
6653105 | Triglia et al. | Nov 2003 | B2 |
6653134 | Prockop et al. | Nov 2003 | B2 |
6660523 | Blom et al. | Dec 2003 | B2 |
6662805 | Frondoza et al. | Dec 2003 | B2 |
6667034 | Palsson et al. | Dec 2003 | B2 |
6667176 | Funk et al. | Dec 2003 | B1 |
6670169 | Schob et al. | Dec 2003 | B1 |
6670175 | Wang et al. | Dec 2003 | B2 |
6673603 | Baetge et al. | Jan 2004 | B2 |
6673606 | Tennekoon et al. | Jan 2004 | B1 |
6677306 | Veis et al. | Jan 2004 | B1 |
6683192 | Baxter et al. | Jan 2004 | B2 |
6685936 | McIntosh et al. | Feb 2004 | B2 |
6685971 | Xu | Feb 2004 | B2 |
6686198 | Melton et al. | Feb 2004 | B1 |
6689324 | Inoue | Feb 2004 | B2 |
6690981 | Kawachi et al. | Feb 2004 | B1 |
6696575 | Schmidt et al. | Feb 2004 | B2 |
6699716 | Sullivan et al. | Mar 2004 | B2 |
6703017 | Peck et al. | Mar 2004 | B1 |
6703209 | Baetscher et al. | Mar 2004 | B1 |
6706293 | Quintanilla Almagro et al. | Mar 2004 | B1 |
6709864 | Pittenger et al. | Mar 2004 | B1 |
6712850 | Vyakarnam et al. | Mar 2004 | B2 |
6719969 | Hogaboam et al. | Apr 2004 | B1 |
6719970 | Costantino et al. | Apr 2004 | B1 |
6720340 | Cooke et al. | Apr 2004 | B1 |
6730314 | Jeschke et al. | May 2004 | B2 |
6730315 | Usala et al. | May 2004 | B2 |
6730510 | Roos et al. | May 2004 | B2 |
6733746 | Daley et al. | May 2004 | B2 |
6734000 | Chin et al. | May 2004 | B2 |
6740493 | Long et al. | May 2004 | B1 |
6759039 | Tsang et al. | Jul 2004 | B2 |
6759245 | Toner et al. | Jul 2004 | B1 |
6761883 | Weissman et al. | Jul 2004 | B2 |
6761887 | Kavalkovich et al. | Jul 2004 | B1 |
6767699 | Polo et al. | Jul 2004 | B2 |
6767737 | Wilson et al. | Jul 2004 | B1 |
6767738 | Gage et al. | Jul 2004 | B1 |
6767740 | Sramek et al. | Jul 2004 | B2 |
6770478 | Crowe et al. | Aug 2004 | B2 |
6777227 | Ricci et al. | Aug 2004 | B2 |
6777231 | Katz et al. | Aug 2004 | B1 |
6780612 | Ford et al. | Aug 2004 | B1 |
6787355 | Miller et al. | Sep 2004 | B1 |
6790455 | Chu et al. | Sep 2004 | B2 |
6793939 | Badylak | Sep 2004 | B2 |
6797269 | Mosca et al. | Sep 2004 | B2 |
6797514 | Berenson et al. | Sep 2004 | B2 |
6800480 | Bodnar et al. | Oct 2004 | B1 |
6802971 | Gorsuch et al. | Oct 2004 | B2 |
6805860 | Alt | Oct 2004 | B1 |
6809117 | Enikolopov et al. | Oct 2004 | B2 |
6811773 | Gentz et al. | Nov 2004 | B1 |
6811776 | Kale et al. | Nov 2004 | B2 |
6814961 | Jensen et al. | Nov 2004 | B1 |
6821513 | Fleming | Nov 2004 | B1 |
6821790 | Mahant et al. | Nov 2004 | B2 |
6828145 | Avital et al. | Dec 2004 | B2 |
6833269 | Carpenter | Dec 2004 | B2 |
6835377 | Goldberg et al. | Dec 2004 | B2 |
6835566 | Smith et al. | Dec 2004 | B2 |
6838284 | de Bruijn et al. | Jan 2005 | B2 |
6841150 | Halvorsen et al. | Jan 2005 | B2 |
6841151 | Stringer | Jan 2005 | B2 |
6841294 | Morrissey et al. | Jan 2005 | B1 |
6841355 | Livant | Jan 2005 | B2 |
6841386 | Kraus et al. | Jan 2005 | B2 |
6841542 | Bartelmez et al. | Jan 2005 | B2 |
6844011 | Faustman | Jan 2005 | B1 |
6844187 | Weschler et al. | Jan 2005 | B1 |
6849051 | Sramek et al. | Feb 2005 | B2 |
6849255 | Gazit et al. | Feb 2005 | B2 |
6849454 | Kelly et al. | Feb 2005 | B2 |
6849662 | Enikolopov et al. | Feb 2005 | B2 |
6852308 | Kohn et al. | Feb 2005 | B2 |
6852321 | Colucci et al. | Feb 2005 | B2 |
6852533 | Rafii et al. | Feb 2005 | B1 |
6855242 | Comninellis et al. | Feb 2005 | B1 |
6855542 | DiMilla et al. | Feb 2005 | B2 |
6863900 | Kadiyala et al. | Mar 2005 | B2 |
6866843 | Habener et al. | Mar 2005 | B2 |
6872389 | Faris | Mar 2005 | B1 |
6875430 | McIntosh et al. | Apr 2005 | B2 |
6887600 | Morrissey et al. | May 2005 | B2 |
6887704 | Peled et al. | May 2005 | B2 |
6908763 | Akashi et al. | Jun 2005 | B1 |
6911201 | Merchav et al. | Jun 2005 | B1 |
6914279 | Lu et al. | Jul 2005 | B2 |
6939955 | Rameshwar | Sep 2005 | B2 |
6943008 | Ma | Sep 2005 | B1 |
6944522 | Karmiy et al. | Sep 2005 | B2 |
6965018 | Mikesell et al. | Nov 2005 | B2 |
6969308 | Doi et al. | Nov 2005 | B2 |
6979308 | McDonald et al. | Dec 2005 | B1 |
6979321 | Geis et al. | Dec 2005 | B2 |
6988004 | Kanno et al. | Jan 2006 | B2 |
7008394 | Geise et al. | Mar 2006 | B2 |
7015037 | Furcht et al. | Mar 2006 | B1 |
7029666 | Bruder et al. | Apr 2006 | B2 |
7033339 | Lynn | Apr 2006 | B1 |
7033823 | Chang | Apr 2006 | B2 |
7041493 | Rao | May 2006 | B2 |
7045098 | Stephens | May 2006 | B2 |
7052517 | Murphy et al. | May 2006 | B2 |
7056493 | Kohn et al. | Jun 2006 | B2 |
7112441 | Uemura et al. | Sep 2006 | B2 |
7118672 | Husain et al. | Oct 2006 | B2 |
7122178 | Simmons et al. | Oct 2006 | B1 |
7160719 | Nyberg | Jan 2007 | B2 |
7169295 | Husain et al. | Jan 2007 | B2 |
7172696 | Martinez et al. | Feb 2007 | B1 |
7175763 | Husain et al. | Feb 2007 | B2 |
7192776 | Stephens | Mar 2007 | B2 |
7195711 | Gorsuch et al. | Mar 2007 | B2 |
7250154 | Kohn et al. | Jul 2007 | B2 |
7270996 | Cannon et al. | Sep 2007 | B2 |
7271234 | Kohn et al. | Sep 2007 | B2 |
7294259 | Cote et al. | Nov 2007 | B2 |
7300571 | Cote et al. | Nov 2007 | B2 |
7303676 | Husain et al. | Dec 2007 | B2 |
7303677 | Cote et al. | Dec 2007 | B2 |
7341062 | Chachques et al. | Mar 2008 | B2 |
7358001 | Morrissey et al. | Apr 2008 | B2 |
7361493 | Hammond et al. | Apr 2008 | B1 |
7368169 | Kohn et al. | May 2008 | B2 |
7378271 | Bader | May 2008 | B2 |
7399872 | Webster et al. | Jul 2008 | B2 |
7416884 | Gemmiti et al. | Aug 2008 | B2 |
7425440 | Malinge et al. | Sep 2008 | B2 |
7435586 | Bartlett et al. | Oct 2008 | B2 |
7438902 | Habener et al. | Oct 2008 | B2 |
7439057 | Frangos et al. | Oct 2008 | B2 |
7452529 | Brown, Jr. et al. | Nov 2008 | B2 |
7491388 | McIntosh et al. | Feb 2009 | B1 |
7494811 | Wolfinbarger, Jr. et al. | Feb 2009 | B2 |
7514074 | Pittenger et al. | Apr 2009 | B2 |
7514075 | Hedrick et al. | Apr 2009 | B2 |
7524676 | Reiter et al. | Apr 2009 | B2 |
7531351 | Marx et al. | May 2009 | B2 |
7534609 | Merchav et al. | May 2009 | B2 |
7572374 | Gorsuch et al. | Aug 2009 | B2 |
7579179 | Bryhan et al. | Aug 2009 | B2 |
7585412 | Gorsuch et al. | Sep 2009 | B2 |
7588938 | Ma | Sep 2009 | B2 |
7598075 | Smith et al. | Oct 2009 | B2 |
7608447 | Cohen et al. | Oct 2009 | B2 |
7659118 | Furcht et al. | Feb 2010 | B2 |
7678573 | Merchav et al. | Mar 2010 | B2 |
7682822 | Noll et al. | Mar 2010 | B2 |
7682823 | Runyon | Mar 2010 | B1 |
7718430 | Antwiler | May 2010 | B2 |
7722896 | Kohn et al. | May 2010 | B2 |
D620732 | Andrews | Aug 2010 | S |
7838122 | Kohn et al. | Nov 2010 | B2 |
7838289 | Furcht et al. | Nov 2010 | B2 |
7892829 | Pittenger et al. | Feb 2011 | B2 |
7919307 | Klaus et al. | Apr 2011 | B2 |
7927587 | Blazer et al. | Apr 2011 | B2 |
7989851 | Lu et al. | Aug 2011 | B2 |
8008528 | Kohn et al. | Aug 2011 | B2 |
8034365 | Baluca | Oct 2011 | B2 |
8075881 | Verfaillie et al. | Dec 2011 | B2 |
8147824 | Maziarz et al. | Apr 2012 | B2 |
8147863 | Kohn et al. | Apr 2012 | B2 |
8158120 | Pittenger et al. | Apr 2012 | B2 |
8158121 | Pittenger et al. | Apr 2012 | B2 |
8252280 | Verfaillie et al. | Aug 2012 | B1 |
8252887 | Bolikal et al. | Aug 2012 | B2 |
8288159 | Warren et al. | Oct 2012 | B2 |
8288590 | Kohn et al. | Oct 2012 | B2 |
8298823 | Warren et al. | Oct 2012 | B2 |
8309347 | Antwiler | Nov 2012 | B2 |
8321145 | Antwiler | Nov 2012 | B2 |
8361453 | Uhrich et al. | Jan 2013 | B2 |
8377683 | Lu et al. | Feb 2013 | B2 |
8383397 | Wojciechowski et al. | Feb 2013 | B2 |
8383806 | Rameshwar | Feb 2013 | B2 |
8399245 | Leuthaeuser et al. | Mar 2013 | B2 |
8415449 | Kohn et al. | Apr 2013 | B2 |
8435781 | Kodama | May 2013 | B2 |
8461289 | Kohn et al. | Jun 2013 | B2 |
8476399 | Bolikal et al. | Jul 2013 | B2 |
8486621 | Luo et al. | Jul 2013 | B2 |
8486695 | Danilkovitch et al. | Jul 2013 | B2 |
8492140 | Smith et al. | Jul 2013 | B2 |
8492150 | Parker et al. | Jul 2013 | B2 |
8524496 | Meiron et al. | Sep 2013 | B2 |
8529888 | Meiron et al. | Sep 2013 | B2 |
8540499 | Page et al. | Sep 2013 | B2 |
8551511 | Brandom et al. | Oct 2013 | B2 |
8580249 | Blazar et al. | Nov 2013 | B2 |
8678638 | Wong | Mar 2014 | B2 |
8785181 | Antwiler | Jul 2014 | B2 |
8852570 | Pittenger et al. | Oct 2014 | B2 |
8852571 | Pittenger et al. | Oct 2014 | B2 |
8852572 | Pittenger et al. | Oct 2014 | B2 |
8852573 | Pittenger et al. | Oct 2014 | B2 |
8852574 | Pittenger et al. | Oct 2014 | B2 |
8852575 | Pittenger et al. | Oct 2014 | B2 |
8895291 | Dilorenzo et al. | Nov 2014 | B2 |
9057045 | Gibbons et al. | Jun 2015 | B2 |
9109193 | Galliher et al. | Aug 2015 | B2 |
9175259 | Nankervis | Nov 2015 | B2 |
9220810 | Ma et al. | Dec 2015 | B2 |
9260698 | Antwiler | Feb 2016 | B2 |
9441195 | Wojciechowski et al. | Sep 2016 | B2 |
9534198 | Page et al. | Jan 2017 | B2 |
9677042 | Stanton, IV et al. | Jun 2017 | B2 |
9725689 | Stanton, IV et al. | Aug 2017 | B2 |
9732313 | Hirschel et al. | Aug 2017 | B2 |
10093956 | Hirschel et al. | Oct 2018 | B2 |
10494421 | Castillo | Dec 2019 | B2 |
20010017188 | Cooley et al. | Aug 2001 | A1 |
20010020086 | Hubbell et al. | Sep 2001 | A1 |
20010021516 | Wei et al. | Sep 2001 | A1 |
20010029046 | Beaulieu | Oct 2001 | A1 |
20010033834 | Wilkison et al. | Oct 2001 | A1 |
20010036663 | Kraus et al. | Nov 2001 | A1 |
20010041687 | Mruk | Nov 2001 | A1 |
20010044413 | Pierce et al. | Nov 2001 | A1 |
20010049139 | Lagasse et al. | Dec 2001 | A1 |
20020015724 | Yang et al. | Feb 2002 | A1 |
20020018804 | Austin et al. | Feb 2002 | A1 |
20020028510 | Sanberg et al. | Mar 2002 | A1 |
20020031757 | Ohgushi et al. | Mar 2002 | A1 |
20020037278 | Ueno et al. | Mar 2002 | A1 |
20020045260 | Hung et al. | Apr 2002 | A1 |
20020064869 | Ebner et al. | May 2002 | A1 |
20020076400 | Katz et al. | Jun 2002 | A1 |
20020077687 | Ahn | Jun 2002 | A1 |
20020082698 | Parenteau et al. | Jun 2002 | A1 |
20020116054 | Lundell et al. | Aug 2002 | A1 |
20020128581 | Vishnoi et al. | Sep 2002 | A1 |
20020128582 | Farrell et al. | Sep 2002 | A1 |
20020128583 | Min et al. | Sep 2002 | A1 |
20020128584 | Brown et al. | Sep 2002 | A1 |
20020130100 | Smith | Sep 2002 | A1 |
20020132343 | Lum | Sep 2002 | A1 |
20020139743 | Critz et al. | Oct 2002 | A1 |
20020142457 | Umezawa et al. | Oct 2002 | A1 |
20020146678 | Benvenisty | Oct 2002 | A1 |
20020146817 | Cannon et al. | Oct 2002 | A1 |
20020150989 | Greene et al. | Oct 2002 | A1 |
20020151056 | Sasai et al. | Oct 2002 | A1 |
20020159981 | Peled et al. | Oct 2002 | A1 |
20020160032 | Long et al. | Oct 2002 | A1 |
20020160510 | Hariri | Oct 2002 | A1 |
20020168765 | Prockop et al. | Nov 2002 | A1 |
20020169408 | Beretta et al. | Nov 2002 | A1 |
20020182241 | Borenstein et al. | Dec 2002 | A1 |
20020182664 | Dolecek et al. | Dec 2002 | A1 |
20020188962 | Denhardt et al. | Dec 2002 | A1 |
20020197240 | Chiu | Dec 2002 | A1 |
20030021850 | Xu | Jan 2003 | A1 |
20030022390 | Stephens | Jan 2003 | A1 |
20030027330 | Lanza et al. | Feb 2003 | A1 |
20030027331 | Yan et al. | Feb 2003 | A1 |
20030032143 | Neff et al. | Feb 2003 | A1 |
20030036168 | Ni et al. | Feb 2003 | A1 |
20030037836 | Blatt et al. | Feb 2003 | A1 |
20030040113 | Mizuno et al. | Feb 2003 | A1 |
20030049236 | Kassem et al. | Mar 2003 | A1 |
20030054331 | Fraser et al. | Mar 2003 | A1 |
20030059851 | Smith | Mar 2003 | A1 |
20030059939 | Page et al. | Mar 2003 | A1 |
20030069650 | Karmiy et al. | Apr 2003 | A1 |
20030078345 | Morrisey | Apr 2003 | A1 |
20030082795 | Shuler et al. | May 2003 | A1 |
20030086915 | Rader et al. | May 2003 | A1 |
20030089471 | Gehr et al. | May 2003 | A1 |
20030092101 | Ni et al. | May 2003 | A1 |
20030101465 | Lawman et al. | May 2003 | A1 |
20030103957 | McKerracher | Jun 2003 | A1 |
20030104568 | Lee | Jun 2003 | A1 |
20030113813 | Heidaran et al. | Jun 2003 | A1 |
20030113910 | Levanduski | Jun 2003 | A1 |
20030124091 | Tuse et al. | Jul 2003 | A1 |
20030124721 | Cheatham et al. | Jul 2003 | A1 |
20030130593 | Gonzalez | Jul 2003 | A1 |
20030133918 | Sherley | Jul 2003 | A1 |
20030138950 | McAllister et al. | Jul 2003 | A1 |
20030143727 | Chang | Jul 2003 | A1 |
20030148152 | Morrisey | Aug 2003 | A1 |
20030149011 | Ackerman et al. | Aug 2003 | A1 |
20030152558 | Luft et al. | Aug 2003 | A1 |
20030157078 | Hall et al. | Aug 2003 | A1 |
20030157709 | DiMilla et al. | Aug 2003 | A1 |
20030161817 | Young et al. | Aug 2003 | A1 |
20030166272 | Abuljadayel | Sep 2003 | A1 |
20030170214 | Bader | Sep 2003 | A1 |
20030180296 | Salcedo et al. | Sep 2003 | A1 |
20030185817 | Thomas et al. | Oct 2003 | A1 |
20030202938 | Rameshwar | Oct 2003 | A1 |
20030203483 | Seshi | Oct 2003 | A1 |
20030204323 | Morrisey | Oct 2003 | A1 |
20030211602 | Atala | Nov 2003 | A1 |
20030211603 | Earp et al. | Nov 2003 | A1 |
20030216718 | Hamblin et al. | Nov 2003 | A1 |
20030219898 | Sugaya et al. | Nov 2003 | A1 |
20030223968 | Yang | Dec 2003 | A1 |
20030224420 | Hellerstein et al. | Dec 2003 | A1 |
20030224510 | Yamaguchi et al. | Dec 2003 | A1 |
20030225010 | Rameshwar | Dec 2003 | A1 |
20030232432 | Bhat | Dec 2003 | A1 |
20030232752 | Freeman et al. | Dec 2003 | A1 |
20030235909 | Hariri et al. | Dec 2003 | A1 |
20040009158 | Sands et al. | Jan 2004 | A1 |
20040009589 | Levenberg et al. | Jan 2004 | A1 |
20040010231 | Leonhardt et al. | Jan 2004 | A1 |
20040014209 | Lassar et al. | Jan 2004 | A1 |
20040018174 | Palasis | Jan 2004 | A1 |
20040018617 | Hwang | Jan 2004 | A1 |
20040023324 | Sakano et al. | Feb 2004 | A1 |
20040023370 | Yu et al. | Feb 2004 | A1 |
20040027914 | Vrane | Feb 2004 | A1 |
20040032430 | Yung et al. | Feb 2004 | A1 |
20040033214 | Young et al. | Feb 2004 | A1 |
20040033599 | Rosenberg | Feb 2004 | A1 |
20040037811 | Penn et al. | Feb 2004 | A1 |
20040037815 | Clarke et al. | Feb 2004 | A1 |
20040038316 | Kaiser et al. | Feb 2004 | A1 |
20040053869 | Andrews et al. | Mar 2004 | A1 |
20040062753 | Rezania et al. | Apr 2004 | A1 |
20040063205 | Xu | Apr 2004 | A1 |
20040067585 | Wang et al. | Apr 2004 | A1 |
20040071668 | Bays et al. | Apr 2004 | A1 |
20040072259 | Scadden et al. | Apr 2004 | A1 |
20040077079 | Storgaard et al. | Apr 2004 | A1 |
20040079248 | Mayer et al. | Apr 2004 | A1 |
20040087016 | Keating et al. | May 2004 | A1 |
20040091936 | West | May 2004 | A1 |
20040096476 | Uhrich et al. | May 2004 | A1 |
20040097408 | Leder et al. | May 2004 | A1 |
20040101959 | Marko et al. | May 2004 | A1 |
20040107453 | Furcht et al. | Jun 2004 | A1 |
20040110286 | Bhatia | Jun 2004 | A1 |
20040115804 | Fu et al. | Jun 2004 | A1 |
20040115806 | Fu | Jun 2004 | A1 |
20040120932 | Zahner | Jun 2004 | A1 |
20040121461 | Honmou et al. | Jun 2004 | A1 |
20040121464 | Rathjen et al. | Jun 2004 | A1 |
20040126405 | Sahatjian et al. | Jul 2004 | A1 |
20040128077 | Koebler et al. | Jul 2004 | A1 |
20040131601 | Epstein et al. | Jul 2004 | A1 |
20040132184 | Dennis et al. | Jul 2004 | A1 |
20040136967 | Weiss et al. | Jul 2004 | A1 |
20040137612 | Baksh | Jul 2004 | A1 |
20040137613 | Vacanti et al. | Jul 2004 | A1 |
20040143174 | Brubaker | Jul 2004 | A1 |
20040143863 | Li et al. | Jul 2004 | A1 |
20040151700 | Harlan et al. | Aug 2004 | A1 |
20040151701 | Kim et al. | Aug 2004 | A1 |
20040151706 | Shakhov et al. | Aug 2004 | A1 |
20040151729 | Michalopoulos et al. | Aug 2004 | A1 |
20040152190 | Sumita | Aug 2004 | A1 |
20040161419 | Strom et al. | Aug 2004 | A1 |
20040171533 | Zehentner et al. | Sep 2004 | A1 |
20040180347 | Stanton et al. | Sep 2004 | A1 |
20040191902 | Hambor et al. | Sep 2004 | A1 |
20040197310 | Sanberg et al. | Oct 2004 | A1 |
20040197375 | Rezania et al. | Oct 2004 | A1 |
20040208786 | Kevy et al. | Oct 2004 | A1 |
20040214275 | Soejima et al. | Oct 2004 | A1 |
20040219134 | Naughton et al. | Nov 2004 | A1 |
20040219136 | Hariri | Nov 2004 | A1 |
20040219563 | West et al. | Nov 2004 | A1 |
20040224403 | Bhatia | Nov 2004 | A1 |
20040229351 | Rodriguez et al. | Nov 2004 | A1 |
20040234972 | Owens et al. | Nov 2004 | A1 |
20040235158 | Bartlett et al. | Nov 2004 | A1 |
20040235160 | Nishikawa et al. | Nov 2004 | A1 |
20040235166 | Prockop et al. | Nov 2004 | A1 |
20040242469 | Lee et al. | Dec 2004 | A1 |
20040258669 | Dzau et al. | Dec 2004 | A1 |
20040259242 | Malinge et al. | Dec 2004 | A1 |
20040259254 | Honmou et al. | Dec 2004 | A1 |
20040260058 | Scheek et al. | Dec 2004 | A1 |
20040260318 | Hunter et al. | Dec 2004 | A1 |
20040265996 | Schwarz et al. | Dec 2004 | A1 |
20050002914 | Rosen et al. | Jan 2005 | A1 |
20050003460 | Nilsson et al. | Jan 2005 | A1 |
20050003527 | Lang et al. | Jan 2005 | A1 |
20050003534 | Huberman et al. | Jan 2005 | A1 |
20050008624 | Peled et al. | Jan 2005 | A1 |
20050008626 | Fraser et al. | Jan 2005 | A1 |
20050009178 | Yost et al. | Jan 2005 | A1 |
20050009179 | Gemmiti et al. | Jan 2005 | A1 |
20050009181 | Black et al. | Jan 2005 | A1 |
20050013804 | Kato et al. | Jan 2005 | A1 |
20050014252 | Chu et al. | Jan 2005 | A1 |
20050014253 | Ehmann et al. | Jan 2005 | A1 |
20050014254 | Kruse | Jan 2005 | A1 |
20050014255 | Tang et al. | Jan 2005 | A1 |
20050019801 | Rubin et al. | Jan 2005 | A1 |
20050019908 | Hariri | Jan 2005 | A1 |
20050019910 | Takagi et al. | Jan 2005 | A1 |
20050019911 | Gronthos et al. | Jan 2005 | A1 |
20050026836 | Dack et al. | Feb 2005 | A1 |
20050031587 | Tsutsui et al. | Feb 2005 | A1 |
20050031595 | Peled et al. | Feb 2005 | A1 |
20050031598 | Levenberg et al. | Feb 2005 | A1 |
20050032122 | Hwang et al. | Feb 2005 | A1 |
20050032207 | Wobus et al. | Feb 2005 | A1 |
20050032209 | Messina et al. | Feb 2005 | A1 |
20050032218 | Gerlach | Feb 2005 | A1 |
20050036980 | Chaney et al. | Feb 2005 | A1 |
20050037488 | Mitalipova et al. | Feb 2005 | A1 |
20050037490 | Rosenberg et al. | Feb 2005 | A1 |
20050037492 | Xu et al. | Feb 2005 | A1 |
20050037493 | Mandalam et al. | Feb 2005 | A1 |
20050037949 | O'Brien et al. | Feb 2005 | A1 |
20050106119 | Brandom et al. | May 2005 | A1 |
20050106127 | Kraus et al. | May 2005 | A1 |
20050112447 | Fletcher et al. | May 2005 | A1 |
20050112762 | Hart et al. | May 2005 | A1 |
20050118712 | Tsai et al. | Jun 2005 | A1 |
20050130297 | Sarem et al. | Jun 2005 | A1 |
20050136093 | Denk | Jun 2005 | A1 |
20050137517 | Blickhan et al. | Jun 2005 | A1 |
20050142162 | Hunter et al. | Jun 2005 | A1 |
20050149157 | Hunter et al. | Jul 2005 | A1 |
20050152946 | Hunter et al. | Jul 2005 | A1 |
20050158289 | Simmons et al. | Jul 2005 | A1 |
20050172340 | Logvinov et al. | Aug 2005 | A1 |
20050175665 | Hunter et al. | Aug 2005 | A1 |
20050175703 | Hunter et al. | Aug 2005 | A1 |
20050178395 | Hunter et al. | Aug 2005 | A1 |
20050178396 | Hunter et al. | Aug 2005 | A1 |
20050180957 | Scharp et al. | Aug 2005 | A1 |
20050181502 | Furcht et al. | Aug 2005 | A1 |
20050182463 | Hunter et al. | Aug 2005 | A1 |
20050183731 | Hunter et al. | Aug 2005 | A1 |
20050186244 | Hunter et al. | Aug 2005 | A1 |
20050186671 | Cannon et al. | Aug 2005 | A1 |
20050187140 | Hunter et al. | Aug 2005 | A1 |
20050196421 | Hunter et al. | Sep 2005 | A1 |
20050208095 | Hunter et al. | Sep 2005 | A1 |
20050244963 | Teplyashin | Nov 2005 | A1 |
20050249731 | Aslan et al. | Nov 2005 | A1 |
20050255118 | Wehner | Nov 2005 | A1 |
20050261674 | Nobis et al. | Nov 2005 | A1 |
20050277577 | Hunter et al. | Dec 2005 | A1 |
20050281790 | Simmons et al. | Dec 2005 | A1 |
20050282733 | Prins et al. | Dec 2005 | A1 |
20050283844 | Furcht et al. | Dec 2005 | A1 |
20060002900 | Binder et al. | Jan 2006 | A1 |
20060008452 | Simmons et al. | Jan 2006 | A1 |
20060019388 | Hutmacher et al. | Jan 2006 | A1 |
20060019389 | Yayon et al. | Jan 2006 | A1 |
20060054941 | Lu et al. | Mar 2006 | A1 |
20060083720 | Fraser et al. | Apr 2006 | A1 |
20060099198 | Thomson et al. | May 2006 | A1 |
20060166364 | Senesac | Jul 2006 | A1 |
20060172008 | Yayon et al. | Aug 2006 | A1 |
20060193840 | Gronthos et al. | Aug 2006 | A1 |
20060228798 | Verfaillie et al. | Oct 2006 | A1 |
20060233834 | Guehenneux et al. | Oct 2006 | A1 |
20060239909 | Anderson et al. | Oct 2006 | A1 |
20060258586 | Sheppard et al. | Nov 2006 | A1 |
20060258933 | Ellis et al. | Nov 2006 | A1 |
20060259998 | Brumbley et al. | Nov 2006 | A1 |
20060280748 | Buckheit | Dec 2006 | A1 |
20060286077 | Gronthos et al. | Dec 2006 | A1 |
20070005148 | Barofsky et al. | Jan 2007 | A1 |
20070011752 | Paleyanda | Jan 2007 | A1 |
20070042462 | Hildinger | Feb 2007 | A1 |
20070065938 | Gronthos et al. | Mar 2007 | A1 |
20070105222 | Wolfinbarger et al. | May 2007 | A1 |
20070116612 | Williamson | May 2007 | A1 |
20070117180 | Morikawa et al. | May 2007 | A1 |
20070122904 | Nordon | May 2007 | A1 |
20070123996 | Sugaya et al. | May 2007 | A1 |
20070160583 | Lange et al. | Jul 2007 | A1 |
20070166834 | Williamson et al. | Jul 2007 | A1 |
20070178071 | Westenfelder | Aug 2007 | A1 |
20070192715 | Kataria et al. | Aug 2007 | A1 |
20070196421 | Hunter et al. | Aug 2007 | A1 |
20070197957 | Hunter et al. | Aug 2007 | A1 |
20070198063 | Hunter et al. | Aug 2007 | A1 |
20070202485 | Nees et al. | Aug 2007 | A1 |
20070203330 | Kretschmar et al. | Aug 2007 | A1 |
20070208134 | Hunter et al. | Sep 2007 | A1 |
20070231305 | Noll et al. | Oct 2007 | A1 |
20070258943 | Penn et al. | Nov 2007 | A1 |
20070274970 | Gordon et al. | Nov 2007 | A1 |
20070275457 | Granchelli et al. | Nov 2007 | A1 |
20070295651 | Martinez et al. | Dec 2007 | A1 |
20070298015 | Beer et al. | Dec 2007 | A1 |
20070298497 | Antwiler | Dec 2007 | A1 |
20080003663 | Bryhan et al. | Jan 2008 | A1 |
20080009458 | Dornan et al. | Jan 2008 | A1 |
20080032398 | Cannon et al. | Feb 2008 | A1 |
20080050770 | Zhang et al. | Feb 2008 | A1 |
20080063600 | Aguzzi et al. | Mar 2008 | A1 |
20080064649 | Rameshwar | Mar 2008 | A1 |
20080069807 | Jy et al. | Mar 2008 | A1 |
20080095676 | Andretta | Apr 2008 | A1 |
20080095690 | Liu | Apr 2008 | A1 |
20080103412 | Chin | May 2008 | A1 |
20080110827 | Cote et al. | May 2008 | A1 |
20080113426 | Smith et al. | May 2008 | A1 |
20080113440 | Gurney et al. | May 2008 | A1 |
20080153077 | Henry | Jun 2008 | A1 |
20080160597 | van der Heiden et al. | Jul 2008 | A1 |
20080166808 | Nyberg | Jul 2008 | A1 |
20080181879 | Catelas et al. | Jul 2008 | A1 |
20080190857 | Beretta et al. | Aug 2008 | A1 |
20080194017 | Esser et al. | Aug 2008 | A1 |
20080206831 | Coffey et al. | Aug 2008 | A1 |
20080220522 | Antwiler | Sep 2008 | A1 |
20080220523 | Antwiler | Sep 2008 | A1 |
20080220524 | Noll et al. | Sep 2008 | A1 |
20080220526 | Ellison et al. | Sep 2008 | A1 |
20080221443 | Ritchie et al. | Sep 2008 | A1 |
20080227189 | Bader | Sep 2008 | A1 |
20080227190 | Antwiler | Sep 2008 | A1 |
20080248572 | Antwiler | Oct 2008 | A1 |
20080254533 | Antwiler | Oct 2008 | A1 |
20080268165 | Fekety et al. | Oct 2008 | A1 |
20080268538 | Nordon et al. | Oct 2008 | A1 |
20080306095 | Crawford | Dec 2008 | A1 |
20090004738 | Merchav et al. | Jan 2009 | A1 |
20090011399 | Fischer | Jan 2009 | A1 |
20090047289 | Denhardt et al. | Feb 2009 | A1 |
20090074728 | Gronthos et al. | Mar 2009 | A1 |
20090075881 | Catelas et al. | Mar 2009 | A1 |
20090076481 | Stegmann et al. | Mar 2009 | A1 |
20090081770 | Srienc et al. | Mar 2009 | A1 |
20090081797 | Fadeev et al. | Mar 2009 | A1 |
20090092608 | Ni et al. | Apr 2009 | A1 |
20090098103 | Madison et al. | Apr 2009 | A1 |
20090098645 | Fang et al. | Apr 2009 | A1 |
20090100944 | Newby | Apr 2009 | A1 |
20090104163 | Deans et al. | Apr 2009 | A1 |
20090104653 | Paldus et al. | Apr 2009 | A1 |
20090104692 | Bartfeld et al. | Apr 2009 | A1 |
20090104699 | Newby et al. | Apr 2009 | A1 |
20090118161 | Cruz | May 2009 | A1 |
20090181087 | Kraus et al. | Jul 2009 | A1 |
20090183581 | Wilkinson et al. | Jul 2009 | A1 |
20090191627 | Fadeev et al. | Jul 2009 | A1 |
20090191632 | Fadeev et al. | Jul 2009 | A1 |
20090191634 | Martin et al. | Jul 2009 | A1 |
20090203065 | Gehman et al. | Aug 2009 | A1 |
20090203129 | Furcht et al. | Aug 2009 | A1 |
20090203130 | Furcht et al. | Aug 2009 | A1 |
20090214382 | Burgess et al. | Aug 2009 | A1 |
20090214481 | Muhs et al. | Aug 2009 | A1 |
20090214652 | Hunter et al. | Aug 2009 | A1 |
20090215022 | Page et al. | Aug 2009 | A1 |
20090227024 | Baker et al. | Sep 2009 | A1 |
20090227027 | Baker et al. | Sep 2009 | A1 |
20090233334 | Hildinger et al. | Sep 2009 | A1 |
20090233353 | Furcht et al. | Sep 2009 | A1 |
20090233354 | Furcht et al. | Sep 2009 | A1 |
20090258379 | Klein et al. | Oct 2009 | A1 |
20090269841 | Wojciechowski et al. | Oct 2009 | A1 |
20090270725 | Leimbach et al. | Oct 2009 | A1 |
20090280153 | Hunter et al. | Nov 2009 | A1 |
20090280565 | Jolicoeur et al. | Nov 2009 | A1 |
20090291890 | Madison et al. | Nov 2009 | A1 |
20100009409 | Hubbell et al. | Jan 2010 | A1 |
20100021954 | Deshayes et al. | Jan 2010 | A1 |
20100021990 | Edwards et al. | Jan 2010 | A1 |
20100028311 | Motlagh et al. | Feb 2010 | A1 |
20100042260 | Antwiler | Feb 2010 | A1 |
20100075410 | Desai et al. | Mar 2010 | A1 |
20100086481 | Baird et al. | Apr 2010 | A1 |
20100090971 | Choi et al. | Apr 2010 | A1 |
20100092536 | Hunter et al. | Apr 2010 | A1 |
20100093607 | Dickneite | Apr 2010 | A1 |
20100105138 | Dodd et al. | Apr 2010 | A1 |
20100111910 | Rakoczy | May 2010 | A1 |
20100129376 | Denhardt et al. | May 2010 | A1 |
20100129912 | Su et al. | May 2010 | A1 |
20100136091 | Moghe et al. | Jun 2010 | A1 |
20100144037 | Antwiler | Jun 2010 | A1 |
20100144634 | Zheng et al. | Jun 2010 | A1 |
20100183561 | Sakthivel et al. | Jul 2010 | A1 |
20100183585 | Van Zant et al. | Jul 2010 | A1 |
20100203020 | Ghosh | Aug 2010 | A1 |
20100230203 | Karayianni | Sep 2010 | A1 |
20100248366 | Fadeev et al. | Sep 2010 | A1 |
20100278933 | Sayeski et al. | Nov 2010 | A1 |
20100285453 | Goodrich | Nov 2010 | A1 |
20100285590 | Verfaillie et al. | Nov 2010 | A1 |
20100291180 | Uhrich | Nov 2010 | A1 |
20100291181 | Uhrich et al. | Nov 2010 | A1 |
20100297234 | Sugino et al. | Nov 2010 | A1 |
20100304427 | Faris et al. | Dec 2010 | A1 |
20100304482 | Deshayes et al. | Dec 2010 | A1 |
20100310524 | Bechor et al. | Dec 2010 | A1 |
20100316446 | Runyon | Dec 2010 | A1 |
20110060463 | Selker et al. | Mar 2011 | A1 |
20110085746 | Wong et al. | Apr 2011 | A1 |
20110111498 | Oh et al. | May 2011 | A1 |
20110129447 | Meretzki et al. | Jun 2011 | A1 |
20110129486 | Meiron | Jun 2011 | A1 |
20110143433 | Oh et al. | Jun 2011 | A1 |
20110159584 | Gibbons et al. | Jun 2011 | A1 |
20110171182 | Abelman | Jul 2011 | A1 |
20110171659 | Furcht et al. | Jul 2011 | A1 |
20110177595 | Furcht et al. | Jul 2011 | A1 |
20110212493 | Hirschel et al. | Sep 2011 | A1 |
20110256108 | Meiron et al. | Oct 2011 | A1 |
20110256160 | Meiron et al. | Oct 2011 | A1 |
20110293583 | Aberman | Dec 2011 | A1 |
20120028352 | Oh et al. | Feb 2012 | A1 |
20120051976 | Lu et al. | Mar 2012 | A1 |
20120058554 | Deshayes et al. | Mar 2012 | A1 |
20120064047 | Verfaillie et al. | Mar 2012 | A1 |
20120064583 | Edwards et al. | Mar 2012 | A1 |
20120086657 | Stanton, IV et al. | Apr 2012 | A1 |
20120089930 | Stanton, IV et al. | Apr 2012 | A1 |
20120118919 | Cianciolo | May 2012 | A1 |
20120122220 | Merchav et al. | May 2012 | A1 |
20120135043 | Maziarz et al. | May 2012 | A1 |
20120145580 | Paruit et al. | Jun 2012 | A1 |
20120156779 | Anneren et al. | Jun 2012 | A1 |
20120178885 | Kohn et al. | Jul 2012 | A1 |
20120189713 | Kohn et al. | Jul 2012 | A1 |
20120208039 | Barbaroux et al. | Aug 2012 | A1 |
20120219531 | Oh et al. | Aug 2012 | A1 |
20120219737 | Sugino et al. | Aug 2012 | A1 |
20120226013 | Kohn et al. | Sep 2012 | A1 |
20120231519 | Bushman et al. | Sep 2012 | A1 |
20120237557 | Lewitus et al. | Sep 2012 | A1 |
20120295352 | Antwiler | Nov 2012 | A1 |
20120308531 | Pinxteren et al. | Dec 2012 | A1 |
20120315696 | Luitjens et al. | Dec 2012 | A1 |
20130004465 | Aberman | Jan 2013 | A1 |
20130039892 | Aberman | Feb 2013 | A1 |
20130058907 | Wojciechowski et al. | Mar 2013 | A1 |
20130059383 | Dijkhuizen Borgart et al. | Mar 2013 | A1 |
20130101561 | Sabaawy | Apr 2013 | A1 |
20130143313 | Niazi | Jun 2013 | A1 |
20130157353 | Dijkhuizen Borgart et al. | Jun 2013 | A1 |
20130259843 | Duda et al. | Oct 2013 | A1 |
20130319575 | Mendyk | Dec 2013 | A1 |
20130323213 | Meiron et al. | Dec 2013 | A1 |
20130337558 | Meiron et al. | Dec 2013 | A1 |
20140004553 | Parker et al. | Jan 2014 | A1 |
20140017209 | Aberman et al. | Jan 2014 | A1 |
20140030805 | Kasuto et al. | Jan 2014 | A1 |
20140051162 | Nankervis | Feb 2014 | A1 |
20140051167 | Nankervis et al. | Feb 2014 | A1 |
20140112893 | Tom et al. | Apr 2014 | A1 |
20140186937 | Smith et al. | Jul 2014 | A1 |
20140193895 | Smith et al. | Jul 2014 | A1 |
20140193911 | Newby et al. | Jul 2014 | A1 |
20140242039 | Meiron et al. | Aug 2014 | A1 |
20140248244 | Danilkovitch et al. | Sep 2014 | A1 |
20140315300 | Oh et al. | Oct 2014 | A1 |
20140342448 | Nagels | Nov 2014 | A1 |
20150004693 | Danilkovitch et al. | Jan 2015 | A1 |
20150024492 | Antwiler | Jan 2015 | A1 |
20150104431 | Pittenger et al. | Apr 2015 | A1 |
20150111252 | Hirschel et al. | Apr 2015 | A1 |
20150125138 | Karnieli et al. | May 2015 | A1 |
20150140654 | Nankervis | May 2015 | A1 |
20150175950 | Hirschel et al. | Jun 2015 | A1 |
20150225685 | Hirschel et al. | Aug 2015 | A1 |
20150247122 | Tom et al. | Sep 2015 | A1 |
20150259749 | Santos et al. | Sep 2015 | A1 |
20160362650 | Wojciechowski et al. | Dec 2016 | A1 |
20160362652 | Page et al. | Dec 2016 | A1 |
20170267966 | Stanton, IV et al. | Sep 2017 | A1 |
20170335270 | Stanton, IV et al. | Nov 2017 | A1 |
20180010082 | Jaques et al. | Jan 2018 | A1 |
20180030398 | Castillo | Feb 2018 | A1 |
20180155668 | Hirschel et al. | Jun 2018 | A1 |
20190194628 | Rao et al. | Jun 2019 | A1 |
Number | Date | Country |
---|---|---|
1016332 | Aug 1977 | CA |
102406926 | Apr 2012 | CN |
3833925 | Sep 1989 | DE |
4007703 | Sep 1991 | DE |
10244859 | Apr 2004 | DE |
10327988 | Jul 2004 | DE |
102012200939 | Jul 2013 | DE |
0220650 | May 1987 | EP |
0201086 | Jan 1992 | EP |
0224734 | Mar 1992 | EP |
750938 | Jan 1997 | EP |
906415 | Apr 1999 | EP |
959980 | Dec 1999 | EP |
1007631 | Jun 2000 | EP |
1028737 | Aug 2000 | EP |
1028991 | Aug 2000 | EP |
1066052 | Jan 2001 | EP |
1066060 | Jan 2001 | EP |
1084230 | Mar 2001 | EP |
1147176 | Oct 2001 | EP |
1220611 | Jul 2002 | EP |
1223956 | Jul 2002 | EP |
1325953 | Jul 2003 | EP |
1437404 | Jul 2004 | EP |
1437406 | Jul 2004 | EP |
1447443 | Aug 2004 | EP |
1452594 | Sep 2004 | EP |
1062321 | Dec 2004 | EP |
1484080 | Dec 2004 | EP |
1498478 | Jan 2005 | EP |
1036057 | Oct 2005 | EP |
1605044 | Dec 2005 | EP |
1756262 | Feb 2007 | EP |
1771737 | Apr 2007 | EP |
1882030 | Jan 2008 | EP |
1908490 | Apr 2008 | EP |
1971679 | Sep 2008 | EP |
1991668 | Nov 2008 | EP |
2200622 | Jun 2010 | EP |
2208782 | Jul 2010 | EP |
2264145 | Dec 2010 | EP |
2027247 | Jan 2011 | EP |
2303293 | Apr 2011 | EP |
2311938 | Apr 2011 | EP |
2331957 | Jun 2011 | EP |
2334310 | Jun 2011 | EP |
2334783 | Jun 2011 | EP |
2361968 | Aug 2011 | EP |
2366775 | Sep 2011 | EP |
2465922 | Jun 2012 | EP |
2481819 | Aug 2012 | EP |
2548951 | Jan 2013 | EP |
2561066 | Feb 2013 | EP |
2575831 | Apr 2013 | EP |
2591789 | May 2013 | EP |
2624845 | Aug 2013 | EP |
2626417 | Aug 2013 | EP |
2641606 | Sep 2013 | EP |
2689008 | Jan 2014 | EP |
2694639 | Feb 2014 | EP |
2697362 | Feb 2014 | EP |
2739720 | Jun 2014 | EP |
2807246 | Dec 2014 | EP |
1414671 | Nov 1975 | GB |
2297980 | Aug 1996 | GB |
2360789 | Oct 2001 | GB |
3285 | May 2007 | HU |
H02245177 | Sep 1990 | JP |
H03047074 | Feb 1991 | JP |
2002-535981 | Oct 2002 | JP |
2003052360 | Feb 2003 | JP |
2003510068 | Mar 2003 | JP |
2005-508393 | Mar 2005 | JP |
2005278564 | Oct 2005 | JP |
2007000038 | Jan 2007 | JP |
2010-523118 | Jul 2010 | JP |
2012506257 | Mar 2012 | JP |
5548207 | Jul 2014 | JP |
5548207 | Jul 2014 | JP |
2019516029 | Jun 2019 | JP |
2019525765 | Sep 2019 | JP |
101228026 | Jan 2013 | KR |
20150002762 | Jan 2015 | KR |
101504392 | Mar 2015 | KR |
101548790 | Aug 2015 | KR |
101553040 | Sep 2015 | KR |
20170076679 | Jul 2017 | KR |
20180027501 | Mar 2018 | KR |
102027596 | Oct 2019 | KR |
20200034790 | Mar 2020 | KR |
20200058433 | May 2020 | KR |
115206 | Apr 2003 | MY |
8602379 | Apr 1986 | WO |
8801643 | Mar 1988 | WO |
8912676 | Dec 1989 | WO |
9002171 | Mar 1990 | WO |
WO-9013306 | Nov 1990 | WO |
WO-9105238 | Apr 1991 | WO |
9107485 | May 1991 | WO |
WO-9106641 | May 1991 | WO |
WO-9109194 | Jun 1991 | WO |
9110425 | Jul 1991 | WO |
9210564 | Jun 1992 | WO |
WO-9425571 | Nov 1994 | WO |
9504813 | Feb 1995 | WO |
9521911 | Aug 1995 | WO |
9524468 | Sep 1995 | WO |
9527041 | Oct 1995 | WO |
WO-9629395 | Sep 1996 | WO |
WO-9639035 | Dec 1996 | WO |
WO-9705826 | Feb 1997 | WO |
9716527 | May 1997 | WO |
WO-9729792 | Aug 1997 | WO |
WO-9739104 | Oct 1997 | WO |
WO-1997-040137 | Oct 1997 | WO |
9822588 | May 1998 | WO |
WO-9831403 | Jul 1998 | WO |
9853046 | Nov 1998 | WO |
WO-9851317 | Nov 1998 | WO |
WO-9851785 | Nov 1998 | WO |
WO-9905180 | Feb 1999 | WO |
WO-9924391 | May 1999 | WO |
WO-9924490 | May 1999 | WO |
WO-9927167 | Jun 1999 | WO |
WO-9949015 | Sep 1999 | WO |
WO-0006704 | Feb 2000 | WO |
WO-0009018 | Feb 2000 | WO |
WO-0016420 | Mar 2000 | WO |
WO-0017326 | Mar 2000 | WO |
WO-0029002 | May 2000 | WO |
WO-0032225 | Jun 2000 | WO |
WO-0044058 | Jul 2000 | WO |
0046354 | Aug 2000 | WO |
WO-0054651 | Sep 2000 | WO |
WO-0056405 | Sep 2000 | WO |
WO-0059933 | Oct 2000 | WO |
WO-0069449 | Nov 2000 | WO |
0075275 | Dec 2000 | WO |
WO-0075196 | Dec 2000 | WO |
WO 0075275 | Dec 2000 | WO |
WO-0077236 | Dec 2000 | WO |
WO-2001000783 | Jan 2001 | WO |
WO-2001011011 | Feb 2001 | WO |
WO-2001018174 | Mar 2001 | WO |
WO-2001021766 | Mar 2001 | WO |
0123520 | Apr 2001 | WO |
WO 0123520 | Apr 2001 | WO |
WO-2001025402 | Apr 2001 | WO |
WO-2001029189 | Apr 2001 | WO |
WO-0122810 | Apr 2001 | WO |
WO-2001034167 | May 2001 | WO |
WO-2001049851 | Jul 2001 | WO |
WO-2001054706 | Aug 2001 | WO |
WO-2001-094541 | Dec 2001 | WO |
0228996 | Apr 2002 | WO |
WO 0228996 | Apr 2002 | WO |
WO-2002042422 | May 2002 | WO |
WO-2002057430 | Jul 2002 | WO |
WO-2002092794 | Nov 2002 | WO |
WO-2002101385 | Dec 2002 | WO |
WO-2003010303 | Feb 2003 | WO |
WO-2003014313 | Feb 2003 | WO |
WO-2003016916 | Feb 2003 | WO |
03024587 | Mar 2003 | WO |
WO-2003023018 | Mar 2003 | WO |
WO-2003023019 | Mar 2003 | WO |
WO-2003025167 | Mar 2003 | WO |
WO-2003029402 | Apr 2003 | WO |
03039459 | May 2003 | WO |
WO-2003040336 | May 2003 | WO |
WO-2003042405 | May 2003 | WO |
WO-2003046161 | Jun 2003 | WO |
WO-2003055989 | Jul 2003 | WO |
WO-2003061685 | Jul 2003 | WO |
WO-2003061686 | Jul 2003 | WO |
WO-2003068961 | Aug 2003 | WO |
WO-2003072064 | Sep 2003 | WO |
WO-2003078609 | Sep 2003 | WO |
WO-2003078967 | Sep 2003 | WO |
WO-2003080816 | Oct 2003 | WO |
WO-2003082145 | Oct 2003 | WO |
WO-2003085099 | Oct 2003 | WO |
WO-2003089631 | Oct 2003 | WO |
WO-2003091398 | Nov 2003 | WO |
WO-2003095631 | Nov 2003 | WO |
03105663 | Dec 2003 | WO |
WO 03105663 | Dec 2003 | WO |
WO-2004001697 | Dec 2003 | WO |
WO-2004012226 | Feb 2004 | WO |
WO-2004016779 | Feb 2004 | WO |
WO-2004018526 | Mar 2004 | WO |
WO-2004018655 | Mar 2004 | WO |
WO-2004026115 | Apr 2004 | WO |
WO-2004029231 | Apr 2004 | WO |
WO-2004042023 | May 2004 | WO |
WO-2004042033 | May 2004 | WO |
WO-2004042040 | May 2004 | WO |
WO-2004044127 | May 2004 | WO |
WO-2004044158 | May 2004 | WO |
WO-2004046304 | Jun 2004 | WO |
WO-2004050826 | Jun 2004 | WO |
WO-2004053096 | Jun 2004 | WO |
WO-2004055155 | Jul 2004 | WO |
WO-2004056186 | Jul 2004 | WO |
WO-2004065616 | Aug 2004 | WO |
WO-2004069172 | Aug 2004 | WO |
WO-2004070013 | Aug 2004 | WO |
WO-2004072264 | Aug 2004 | WO |
WO-2004073633 | Sep 2004 | WO |
WO-2004074464 | Sep 2004 | WO |
WO-2004076642 | Sep 2004 | WO |
WO-2004076653 | Sep 2004 | WO |
2004090112 | Oct 2004 | WO |
WO-2004087870 | Oct 2004 | WO |
WO-2004094588 | Nov 2004 | WO |
WO-2004096975 | Nov 2004 | WO |
WO-2004104166 | Dec 2004 | WO |
WO-2004106499 | Dec 2004 | WO |
WO-2004113513 | Dec 2004 | WO |
WO-2005001033 | Jan 2005 | WO |
WO-2005001081 | Jan 2005 | WO |
WO-2005003320 | Jan 2005 | WO |
WO-2005007799 | Jan 2005 | WO |
WO-2005010172 | Feb 2005 | WO |
WO-2005011524 | Feb 2005 | WO |
WO-2005012480 | Feb 2005 | WO |
WO-2005012510 | Feb 2005 | WO |
WO-2005012512 | Feb 2005 | WO |
WO-05014775 | Feb 2005 | WO |
WO-2005028433 | Mar 2005 | WO |
WO-05044972 | May 2005 | WO |
WO-2005056747 | Jun 2005 | WO |
WO-05051316 | Jun 2005 | WO |
WO-2005063303 | Jul 2005 | WO |
WO-2005075636 | Aug 2005 | WO |
2005087915 | Sep 2005 | WO |
2005104755 | Nov 2005 | WO |
WO-2005107760 | Nov 2005 | WO |
WO-2006009291 | Jan 2006 | WO |
2006026835 | Mar 2006 | WO |
WO-2006032075 | Mar 2006 | WO |
WO-2006032092 | Mar 2006 | WO |
2006037022 | Apr 2006 | WO |
WO-2006108229 | Oct 2006 | WO |
WO-2006113881 | Oct 2006 | WO |
WO-2006121445 | Nov 2006 | WO |
WO-06124021 | Nov 2006 | WO |
WO-06129312 | Dec 2006 | WO |
2007038572 | Apr 2007 | WO |
2007059473 | May 2007 | WO |
2007117765 | Oct 2007 | WO |
WO-2007115367 | Oct 2007 | WO |
WO-2007115368 | Oct 2007 | WO |
2007136821 | Nov 2007 | WO |
2007139742 | Dec 2007 | WO |
2007139746 | Dec 2007 | WO |
2007139747 | Dec 2007 | WO |
2007139748 | Dec 2007 | WO |
WO-2008006168 | Jan 2008 | WO |
WO-2008011664 | Jan 2008 | WO |
WO-2008017128 | Feb 2008 | WO |
WO-2008028241 | Mar 2008 | WO |
WO-08040812 | Apr 2008 | WO |
2008073635 | Jun 2008 | WO |
WO 2008109674 | Sep 2008 | WO |
WO-2008116261 | Oct 2008 | WO |
WO-2008149129 | Dec 2008 | WO |
WO-2009026635 | Mar 2009 | WO |
WO 2009034186 | Mar 2009 | WO |
WO-09058146 | May 2009 | WO |
WO-09080054 | Jul 2009 | WO |
WO-09081408 | Jul 2009 | WO |
WO-2009140452 | Nov 2009 | WO |
WO-09132457 | Nov 2009 | WO |
WO-2009144720 | Dec 2009 | WO |
WO-10005527 | Jan 2010 | WO |
WO-2010019886 | Feb 2010 | WO |
WO-10014253 | Feb 2010 | WO |
WO-10019997 | Feb 2010 | WO |
WO-2010026573 | Mar 2010 | WO |
WO-2010026574 | Mar 2010 | WO |
WO-2010026575 | Mar 2010 | WO |
2010036760 | Apr 2010 | WO |
WO-2010059487 | May 2010 | WO |
WO-10061377 | Jun 2010 | WO |
WO-10068710 | Jun 2010 | WO |
WO-10071826 | Jun 2010 | WO |
WO-10083385 | Jul 2010 | WO |
WO-10111255 | Sep 2010 | WO |
WO-10119036 | Oct 2010 | WO |
WO-10123594 | Oct 2010 | WO |
WO-2011025445 | Mar 2011 | WO |
2011098592 | Aug 2011 | WO |
2011130617 | Oct 2011 | WO |
WO-2011132087 | Oct 2011 | WO |
WO-2011147967 | Dec 2011 | WO |
WO-2012072924 | Jun 2012 | WO |
WO-2012127320 | Sep 2012 | WO |
WO-2012138968 | Oct 2012 | WO |
WO-2012140519 | Oct 2012 | WO |
2012171026 | Dec 2012 | WO |
2012171030 | Dec 2012 | WO |
2013085682 | Jun 2013 | WO |
WO-2013110651 | Aug 2013 | WO |
WO-2014037862 | Mar 2014 | WO |
WO-2014037863 | Mar 2014 | WO |
WO-2014068508 | May 2014 | WO |
WO-2014128306 | Aug 2014 | WO |
WO-2014128634 | Aug 2014 | WO |
WO-2014131846 | Sep 2014 | WO |
WO-2014141111 | Sep 2014 | WO |
WO-2015004609 | Jan 2015 | WO |
2015059714 | Apr 2015 | WO |
2015069943 | May 2015 | WO |
WO 2015073913 | May 2015 | WO |
WO 2015073918 | May 2015 | WO |
2015118148 | Aug 2015 | WO |
2015118149 | Aug 2015 | WO |
WO-2015131143 | Sep 2015 | WO |
2016130940 | Aug 2016 | WO |
2017072201 | May 2017 | WO |
2017158611 | Sep 2017 | WO |
2017207822 | Dec 2017 | WO |
2018183426 | Oct 2018 | WO |
2019155032 | Aug 2019 | WO |
2019238919 | Dec 2019 | WO |
2020020569 | Jan 2020 | WO |
2020079274 | Apr 2020 | WO |
Entry |
---|
Housler et al. “Compartmental hollow fiber capillary membrane-based bioreactor technology for in vitro studies on red blood cell lineage direction of hematopoietic stem cells”, Tissue Engineering, Part C: Methods, 18:2 133-142 (Year: 2011). |
Cao et al. “The hollow fiber bioreactor as a stroma-supported, serum-free ex vivo expansion platform for human umbilical cord blood cells”, Biotechnology Journal, 9:7 980-989 (Year: 2014). |
Smith et al., Expansion of CD34+KDR+ cells in cord blood after culture with TPO, FLT-3L, SCF, and VEGF, Abstracts/Experimental Hematology, 28, p. 94 (Year: 2000). |
Mandalam et al., Ex vivo expansion of bone marrow and cord blood cells to produce stem and progenitor cells for hematopoietic reconstruction, Military Medicine, 167, pp. 78-81 (Year: 2002). |
Alakel, et al. Direct contact with mesenchymal stromal cells affects migratory behavior and gene expression profile of CD133+ hematopoietic stem cells during ex vivo expansion, Experimental Hematology, 37, pp. 504-513, (Year: 2009). |
Lu et al., Galactosylated poly(vinylidene difluoride) hollow fiber bioreactor for hepatocyte culture, Tissue Engineering, 11(11/12): 1667-1677. (Year: 2005). |
Godara et al., Mini-review Design of bioreactors for mesenchymal stem cell tissue engineering, Journal of Chemical Technology and Biotechnology, 83:408-420. (Year: 2008). |
Shen et al., Residues 39-56 of stem cell factor protein sequence are capable of stimulating the expansion of cod blood CD34+ cells, PLOS One, 1-14. (Year: 2015). |
Cao et al., The hollow fiber bioreactor as a stroma-supported, serum-free ex vivo expansion platform for human umbilical cord blood cells, Biotechnology Journal, 9: 980-989. (Year: 2014). |
Yao et al., A systematic strategy to optimize ex vivo expansion medium for human hematopoietic stem cells derived from umbilical cord blood mononuclear cells, Experimental Hematology, 32: 720-727. (Year: 2004). |
Stemcell2max, media fact sheet. (Year: 2015). |
Abumiya et al., “Shear Stress Induces Expression of Vascular Endothelial Growth Factor Receptor Flk-1/KDR Through the CT-Rich Sp1 Binding Site,” Ateriosclerosis, Thrombosis, and Vascular Biology, vol. 22, Jun. 2002, pp. 907-913. |
Akiyama et al., “Ultrathin Poly(N-isopropylacrylamide) Grafted Layer on Polystyrene Surfaces for Cell Adhesion/Detachment Control,” Langmuir, vol. 20, No. 13, May 26, 2004, pp. 5506-5511. |
Akram et al., “Mesenchymal Stem Cells Promote Alveolar Epithelial Cell Wound Repair in vitro through Distinct Migratory and Paracrine Mechanisms,” Respiratory Research, vol. 14, No. 9, 2013, pp. 1-16. |
Anamelechi et al., “Streptavidin Binding and Endothelial Cell Adhesion to Biotinylated Fibronectin,” Langmuir, vol. 23, No. 25, Dec. 4, 2007, pp. 12583-12588. |
Azar et al., “Heart Rates of Male and Female Sprague-Dawley and Spontaneously Hypertensive Rats Housed Singly or in Groups,” Journal of the American Association for Laboratory Animal Science, vol. 50, No. 2, Mar. 2011, pp. 175-184. |
Baecher-Allan et al., “CD4+CD25high Regulatory Cells in Human Peripheral Blood,” The Journal of Immunology, vol. 167, 2001, pp. 1245-1253. |
Boitano et al., “Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells,” Science, vol. 329, No. 5997, published Sep. 10, 2010. corrected May 6, 2011, pp. 1345-1348. |
Brunstein et al., “Infusion of ex vivo Expanded T Regulatory Cells in Adults Transplanted with Umbilical Cord Blood: Safety Profile and Detection Kinetics,” Blood, vol. 117, No. 3, Jan. 20, 2011, pp. 1061-1070. |
Bryce et al., “In vitro Micronucleus Assay Scored by Flow Cytometry Provides a Comprehensive Evaluation of Cytogenetic Damage and Cytotoxicity,” Mutation Research, vol. 630, Mar. 19, 2007, pp. 78-91. |
Bryce et al., “Interlaboratory Evaluation of a Flow Cytometric, High Content in vitro Micronucleus Assay,” Mutation Research, vol. 650, Jan. 7, 2008, pp. 181-195. |
Camacho Villa et al., “CD133+CD34+ and CD133+CD38+ Blood Progenitor Cells as Predictors of Platelet Engraftment in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation,” Transfusion and Apheresis Science, vol. 46, 2012, pp. 239-244. |
Cano et al., “Immobilization of endo-1,4-β-xylanase on Polysulfone Acrylate Membranes: Synthesis and Characterization,” Journal of Membrane Science, vol. 280, Feb. 28, 2006, pp. 383-388. |
Carvell et al., “Monitoring Live Biomass in Disposable Bioreactors,” BioProcess International, vol. 14, No. 3, Mar. 2016, pp. 40-48. |
Carvell et al., “On-line Measurements and Control of Viable Cell Density in Cell Culture Manufacturing Processes Using Radio Frequency Impedance,” Cytotechnology, 2006, vol. 50, pp. 35-48. |
Cuchiara et al., “Covalent Immobilization of SCF and SDF1α for in vitro Culture of Hematopoietic Progenitor Cells,” Acta Biomaterials, vol. 9, No. 12, Dec. 2013, pp. 9258-9269. |
Da Silva et al., “Smart Thermoresponsive Coatings and Surfaces for Tissue Engineering; Switching Cell-Material Boundaries,” Trends in Biotechnology, vol. 15, No. 12, 2007, pp. 577-583. |
Garlie et al., “T Cells Coactivated with Immobilized Anti-CD3 and Anti-CD28 as Potential Immunotherapy for Cancer,” Journal of Immunotherapy, vol. 22, No. 4, 1999, pp. 336-345. |
The Effect of Rocking Rate and Angle on T Cell Cultures Grown in XuriTM Cell Expansion Systems, GE Healthcare UK Limited, Cell therapy bioreactor systems, Application note 29-1166-55 AA, Aug. 2014, www.gelifesciences.com/xuri. |
Hao et al., “A Functional Comparison of CD34+ CD38− Cells in Cord Blood and Bone Marrow,” Blood, vol. 86, No. 10, Nov. 15, 1995, pp. 3745-3753. |
Harimoto et al., “Novel Approach for Achieving Double-Layered Cell Sheets Co-Culture: Overlaying Endothelial Cell Sheets onto Monolayer Hepatocytes Utilizing Temperature-Responsive Culture Dishes,” Journal of Biomedical Material Research, vol. 62, 2002, pp. 464-470. |
Högstedt et al., “Frequency and Size Distribution of Micronuclei in Lymphocytes Stimulated with Phytohemagglutinin and Pokeweed Mitogen in Workers Exposed to Piperazine,” Hereditas, vol. 109, 1998, pp. 139-142. |
Infanger et al., “Simulated weightlessness changes the cytoskeleton and extracellular matrix proteins in papillary thyroid carcinoma cells”, Cell and Tissue Research, vol. 324, No. 2, 2006, pp. |
Itkin et al., “SDF-1 Keeps HSC Quiescent at Home,” Blood, vol. 117, No. 2, Jan. 13, 2011, pp. 373-374. |
Jang et al., “Syndecan-4 Proteoliposomes Enhance Fibroblast Growth Factor-2 (FGF-2)-Induced Proliferation, Migration, and Neovascularization of Ischemic Muscle,” PNAS, vol. 109, No. 5, Jan. 31, 2012, pp. 1679-1684. |
Johansson et al., “Pancreatic Islet Survival and Engraftment Is Promoted by Culture on Functionalized Spider Silk Matrices,” PLoS One, Jun. 19, 2015, pp. 1-21. |
Jones et al., “Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System”, Cytotherapy, 2013; 15: 1323-1339. |
Klein et al., “Affinity Membranes Prepared from Hydrophilic Coatings on Microporous Polysulfone Hollow Fibers,” Journal of Membrane Science, vol. 90, 1994, pp. 69-80. |
Koestenbauer et al., “Protocols for Hematopoietic Stem Cell Expansion from Umbilical Cord Blood,” Cell Transplantation, vol. 18, May 6, 2009, pp. 1059-1068. |
Koller et al., “Clinical-scale Human Umbilical Cord Blood Cell Expansion in a Novel Automated Perfusion Culture System,” Bone Marrow Transplantation, vol. 21, 1998, pp. 653-663. |
Lang et al., “Generation of Hematopoietic Humanized Mice in the Newborn BALB/C-Rag2null II2rynull Mouse Model: A Multivariable Optimization Approach,” Clinical Immunology, vol. 140, Apr. 14, 2011, pp. 102-116. |
Lataillade et al., “Chemokine SDF-1 Enhances Circulating CD341 Cell Proliferation in Synergy with Cytokines: Possible Role in Progenitor Survival,” Blood, vol. 95, No. 3, Feb. 1, 2000, pp. 756-768. |
Li et al., “Heparin-induced Conformation Changes of Fibronectin within the Extracellular Matrix Promote hMSC Osteogenic Differentiation,” Biomaterials Science, vol. 3, 2015, pp. 73-84. |
Liu et al., “Ex vivo Expansion of Hematopoietic Stem Cells Derived from Umbilical Cord Blood in Rotating Wall Vessel”, Journal of Biotechnology, 2006, 124:592-601. Abstract only. |
Malin et al., “Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectroscopy,” Clinical Chemistry, vol. 45, No. 9, 1999, pp. 1651-1658. |
Marek-Trzonkowska et al., “Administration of CD4+ CD25high CD127-Regulatory T Cells Preserves β-Cell Function in Type 1 Diabetes in Children,” Diabetes Care, vol. 35, No. 9, Sep. 2012, pp. 1817-1820. |
Murugappan et al., “Human Hematopoietic Progenitor Cells Grow Faster under Rotational Laminar Flows,” Biotechnology Progress—Cell Culture & Tissue Engineering, Online, Apr. 22, 2010. |
Nankervis et al., “Shear Stress Conditions in the Quantum Cell Expansion System”, Poster Session—TERMIS AM Annual Conference 2013, Nov. 12, 2013. |
Nelson et al., “Emergent Patterns of Growth Controlled by Multicellular Form and Mechanics,” PNAS, vol. 102, No. 33, Aug. 16, 2005, pp. 11594-11599. |
Nguyen et al., “QUANTUM® Cell Expansion System: Automated Expansion of Human Mesenchymal Stem Cells from Precultured Cells Using the Quantum Cell Expansion System”, Terumo BCT, Inc., 2012. |
Nicolette et al., “In Vitro Micronucleus Screening of Pharmaceutical Candidates by Flow Cytometry in Chinese Hamster V79 Cells,” Environmental and Molecular Mutagenesis, vol. 52, Oct. 20, 2010, pp. 355-362. |
Nugent et al., “Adventitial Endothelial Implants Reduce Matrix Metalloproteinase-2 Expression and Increase Luminal Diameter in Porcine Arteriovenous Grafts,” Journal of Vascular Surgery, vol. 46, No. 3, Sep. 2007, pp. 548-556.e2. |
Okano et al., “Mechanism of Cell Detachment from Temperature-Modulated, Hydrophilic-Hydrophobic Polymer Surfaces,” Biomaterials, vol. 16, No. 4, 1995, pp. 297-303. |
Putnam et al., “Expansion of Human Regulatory T-Cells from Patients with Type 1 Diabetes,” Diabetes, vol. 58, Mar. 2009, pp. 652-662. |
Rodrigues et al., “Stem Cell Cultivation in Bioreactors,” Biotechnology Advances, vol. 29, Jun. 25, 2011, pp. 815-829. |
Ronco et al., “Blood and Dialysate Flow Distributions in Hollow-Fiber Hemodialyzers Analyzed by Computerized Helical Scanning Technique,” Journal of the American Society of Nephrology, vol. 13, 2002, pp. S53-S61. |
Ryu et al., “Near-infrared Light Responsive Synthetic c-di-GMP Module for Optogenetic Applications,” ACS Synthetic Biology, vol. 3, Jan. 28, 2014, pp. 802-810. |
Shimizu et al., “Fabrication of Pulsatile Cardiac Tissue Grafts Using a Novel 3-Dimensional Cell Sheet Manipulation Technique and Temperature-Responsive Cell Culture Surfaces,” Circulation Research, vol. 90, Feb. 22, 2002, e40-e48, pp. 1-9. |
Smith et al., “Expansion of Neutrophil Precursors and Progenitors in Suspension Cultures of CD34+ Cells Enriched from Human Bone Marrow,” Experimental Hematology, vol. 21, 1993, pp. 870-877. |
Takezawa et al., “Cell Culture on a Thermo-responsive Polymer Surface,” Nature, Bio/Technology, vol. 8, Sep. 1990, pp. 854-856. |
Tiziani et al., “Metabolomic Profiling of Drug Response in Acute Myeloid Leukaemia Cell lines,” PLoS One, vol. 4, Issue 1, Jan. 22, 2009, e4251. |
Ueda et al., “Interaction of Natural Killer Cells with Neutrophils Exerts a Significant Antitumor Immunity in Hematopoietic Stem Cell Transplantation Recipients,” Cancer Medicine, vol. 5, No. 1, 2016 pp. 49-60. |
Urbich et al., “Fluid Shear Stress-induced Transcriptional Activation of the Vascular Endothelial Growth Factor Receptor-2 Gene Requires Sp1-Dependent DNA Binding,” FEBS Letters, 535, 2003, pp. 87-93. |
Von Laer, “Loss of CD38 Antigen on CD34 CD38 Cells during Short-term Culture,” Leukemia, Correspondence, 1999 pp. 947-948. |
Wagner et al., “Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-alone Graft,” Cell Stem Cell, Jan. 7, 2016, vol. 18, pp. 144-155. |
Weaver et al., “An Analysis of Engraftment Kinetics as a Function of the CD34 Content of the Peripheral Blood Progenitor Cell Collections in 692 Patients after the Administration of Myeloblative Chemotherapy,” Blood, vol. 86, No. 10, Nov. 15, 1995, pp. 3691-3969. |
Yang et al., “Suspension Culture of Mammalian Cells Using Thermosensitive Microcarrier that Allows Cell Detachment without Proteolytic Enzyme Treatment,” Cell Transplantation, vol. 19, Aug. 18, 2010, pp. 1123-1132. |
Yi et al., “A Readily Modified Polyethersulfone with Amino-Substituted Groups: Its Amphiphilio Copolymer Synthesis and Membrane Application,” Polymer, vol. 53, Dec. 2, 2011, pp. 350-358. |
Zheng et al., “Differential Effects of Cyclic and Static Stretch on Coronary Microvascular Endothelial Cell Receptors and Vasculogenic/Angiogenic Responses,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 295, Aug. 2008, H794-H800. |
Biovest International, “AutovaxID(TM): advanced hollow fibre bioreactors with automated lactate control yield higher density monoclonal antibody production”, VWRbioMarke, No. 21, Sep. 2008, pp. 10-11. |
Chang et al., “Membrane Bioreactors: Present and Prospects”, Advances in Biochemical Engineering, 1991, vol. 44, pp. 27-64. |
Chang, Ho Nam, “Membrane Bioreactors: Engineering Aspects”, Biotech. Adv., 1987, vol. 5, pp. 129-145. |
Clausen et al., “Lactate as an Indicator of Terminating Time in Insect Cell Culture Baculovirus Expression Vector Systems”, Biotechnology Techniques, vol. 10, No. 10, Oct. 1996, pp. 721-726. |
Edgington, Stephen M., “New Horizons for Stem-Cell Bioreactors”, Biotechnology, Oct. 1992, vol. 10, pp. 1099-1106. |
Gastens et al., “Good Manufacturing Practice-Compliant Expansion of Marrow-Derived Stem and Progenitor Cells for Cell Therapy”, Cell Transplantation, 2007, vol. 16, pp. 685-696. |
Gerlach, J.C. et al., “Comparison of hollow fibre membranes for hepatocyte immobilization in bioreactors,” The International Journal of Artificial Organs, 1996, vol. 19 No. 10, pp. 610-616. |
Gloeckner et al., “New Miniaturized Hollow-Fiber Bioreacter for in Vivo Like Cell Culture, Cell Expansion, and Production of Cell-Derived Products”, Biotechnol. Prog., Aug. 21, 2001, vol. 17, No. 5, pp. 828-831. |
Gramer et al., “Screening Tool for Hollow-Fiber Bioreactor Process Development”, Biotechnol. Prog., 1998, vol. 14, pp. 203-209. |
Grayson et al., “Effects of Hypoxia on Human Mesenchymal Stem Cell Expansion and Plasticity in 3D Constructs”, J. Cellular Physiology, 2006, 207:331-339. |
Hirschel et al., “An Automated Hollow Fiber System for the Large Scale Manufacture of Mammalian Cell Secreted Product”, Large Scale Cell Culture Technology, ed. Bjorn K. Lydersen, Hanser Publishers, 1987, pp. 113-144. |
Lloyd, J.R. et al., “Hollow-Fibre bioreactors compared to batch and chemostat culture for the production of a recombinant toxoid by a marine Vibrio,” Appl. Microbiol Biotechnol, Aug. 1997, vol. 48, pp. 155-161. |
Neumann, Detlef et al., “Bioreaktorsteurung mit grafischer Bedienoberflache,” ATP Automatisierungstechnische Praxis, Mar. 1995, pp. 16-23, vol. 37, No. 3, Munchen, DE. (English language translation included). |
Nielsen, Lars Keld, “Bioreactors for Hematopoietic Cell Culture”, Annu. Rev. Biomed. Eng., 1999, vol. 1, pp. 129-152. |
Ozturk et al., “Real-Time Monitoring and Control of Glucose and Lactate Concentrations in a Mammalian Cell Perfusion Reactor”, Biotechnology and Bioengineering, vol. 53, No. 4, Feb. 20, 1997, pp. 372-378. |
Pörtner et al., “An Overview on Bioreactor Design, Prototyping and Process Control for Reproducible Three-Dimensional Tissue Culture”, Drug Testing in Vitro: Breakthroughs and Trends in Cell Culture Technology, ed. Uwe Marx and Volker Sandig, 2007, Wiley-VCH, pp. 53-78. |
Sauer, I. et al., “Extracorporeal liver support based on primary human liver cells and albumin dialysis—treatment of patient with primary graft non function,” Journal of Hepatology, Oct. 2003, vol. 39 No. 4, pp. 649-653. |
Wang et al., “Influence of Oxygen on the Proliferation and Metabolism of Adipose Derived Adult Stem Cells”, J. Cellular Physiology, 2005, 204:184-161. |
Zhao et al., “Effects of Oxygen Transport on 3-D Human Mesenchymal Stem Cell Metabolic Activity in Perfusion and Static Cultures: Experiments and Mathematical Model”, Biotechnol. Prog., 2005, 21, 1269-1280. |
Zhao et al., “Perfusion Bioreactor System for Human Mesenchymal Stem Cell Tissue Engineering: Dynamic Cell Seeding and Construct Development”, Biotechnology and Bioengineering, Aug. 20, 2005, vol. 91, No. 4, pp. 482-493. |
Official Action (with English translation) for Japan Patent Application No. 2018-561526, dated Dec. 22, 2022, 11 pages. |
Afzali B, Edozie FC, Fazekasova H, Scotta C, Mitchell PJ, Canavan JB, Kordasti SY, Chana PS, Ellis R, Lord GM, John S, Hilton R, Lechler RI, Lombardi G. Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation. Clin J Am Soc Nephrol. 2013;8(8):1396-405. |
Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. Fibroblasts and Their Transformations: The Connective-Tissue Cell Family. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26889. |
Alenazi, Noof A., et al. “Modified polyether-sulfone membrane: A mini review.” Designed monomers and polymers 20.1 (2017): 532-546. |
Almeida L, Lochner M, Berod L, Sparwasser T. Metabolic pathways in T cell activation and lineage differentiation. Semin Immunol. 2016;28(5):514-524. |
Amy Putnam, Todd M. Brusko, Michael R. Lee, Weihong Liu, Gregory L. Szot, Taumoha Ghosh, Mark A. Atkinson, and Jeffrey A. Bluestone. Expansion of human regulatory T-Cells from patients with Type 1 Diabetes. Diabetes, 58: 652-662, 2009. |
Anurathapan et al., “Engineered T cells for cancer treatment,” Cytotherapy, vol. 16, pp. 713-733, 2014. |
Aronowski J, Samways E, Strong R, Rhoades HM, Grotta JC. An alternative method for the quantitation of neuronal damage after experimental middle cerebral artery occlusion in rats: Analysis of behavioral deficit. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1996; 16:705-713. |
Arrigoni, Chiara, et al. “Rotating versus perfusion bioreactor for the culture of engineered vascular constructs based on hyaluronic acid.” Biotechnology and bioengineering 100.5 (2008): 988-997. |
Bai, Tao, et al. “Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel.” Nature medicine 25.10 (2019): 1566-1575. |
Bai/Delaney (Nohla Therapeutics) showed that expanding Cord Blood-derived CD34+CD38-CD45RA-HSPCs in a biodegradable zwitterionic hydrogel with a rNotch ligand cocktail for 24 days mitigated HSPC differentiation and promoted self-renewal of lymphoid and myeloid cell phenotypes in an NSG mouse model (Nature Medicine, 2019). |
Ballas CB, Zielske SP, Gerson SL (2002) Adult bone marrow stem cells for cell and gene therapies: implications for greater use. J Cell Biochem Suppl 38: 20-28. |
Ballke C, Gran E, Baekkevold ES, Jahnsen FL. Characterization of Regulatory T-Cell Markers in CD4+ T Cells of the Upper Airway Mucosa. PLoS One. 2016;11(2):e0148826. |
Baraniak PR, McDevitt TC (2010) Stem cell paracrine actions and tissue regeneration. Regen Med 5(1): 121-143. |
Barckhausen C, Rice B, Baila S, et al. (2016) GMP-Compliant Expansion of Clinical-Grade Human Mesenchymal Stromal/Stem Cells Using a Closed Hollow Fiber Bioreactor. Methods Mol Biol 1416: 389-412. |
Barker et al. “CD34+ Cell Content of 126 341 Cord Blood Units in the US Inventory: Implications for Transplantation and Banking,” blood Advances, vol. 3, No. 8, pp. 1267-1271, Apr. 23, 2019. |
Barker, Juliet N., et al. “CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking.” Blood advances 3.8 (2019): 1267-1271. |
Bazarian JJ, Cernak I, Noble-Haeusslein L, Potolicchio S, Temkin N. Long-term neurologic outcomes after traumatic brain injury. The Journal of head trauma rehabilitation. 2009;24:439-451. |
Bending D, Pesenacker AM, Ursu S, Wu Q, Lom H, Thirugnanabalan B, Wedderburn LR. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol. 2014;193(6):2699-708. |
Berendse M, Grounds MD, Lloyd CM (2003) Myoblast structure affects subsequent skeletal myotube morphology and sarcomere assembly. Exp Cell Res 291(2): 435-450. |
Bernard, A., Payton, Mar. 1995. “Fermentation and Growth of Escherichia coli for Optimal Protein Production”. |
Berney SM, Schaan T, Wolf RE, van der Heyde H, Atkinson TP. CD2 (OKT11) augments CD3-mediated intracellular signaling events in human T lymphocytes. J Investig Med. 2000;48(2):102-9. |
Bioheart Clinical Trial Clinica 1302 Apr. 18, 2008. |
Biomolecular and Cellular Interactions with the Hollow Fiber Membrane Currently Used in the Quantum® Cell Expansion System. 12th NJ Symposium on Biomaterials Science, Oct. 6-7, 2014, New Brunswick, NJ. |
Blache C, Chauvin JM, Marie-Cardine A, Contentin N, Pommier P, Dedreux I, Francois S, Jacquot S, Bastit D, Boyer O. Reduced frequency of regulatory T cells in peripheral blood stem cell compared to bone marrow transplantations. Biol Blood Marrow Transplant. 2010;16(3):430-4. |
Bluestone et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Science Translational Medicine 7(315):1-34, 2015. |
Bluestone JA, Tang Q. Treg cells-the next frontier of cell therapy. Science. 2018;362(6411):154-155. |
Bluestone, Jeffrey A., et al. “Type 1 diabetes immunotherapy using polyclonal regulatory T cells.” Science translational medicine 7.315 (2015): 315ra189-315ra189. |
Blum S, Moore AN, Adams F, Dash Pk. A mitogen-activated protein kinase cascade in the ca1/ca2 subfield of the dorsal hippocampus is essential for long-term spatial memory. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1999;19:3535-3544. |
Bojun Li et al. Heparin-induced conformation changes of fibronectin within the extracellular matrix promote hMSC osteogenic differentiation. Biomaterials Science 3: 73-84, 2015. |
Boquest AC, Shahdadfar A, Brinchmann JE, Collas P. Isolation of Stromal Stem Cells from Human Adipose Tissue. Methods Mol Biol. 2006;325:35-46. doi: 10.1385/1-59745-005-7:35. PMID: 16761717. |
Borden, M. and Longo, M., “Dissolution Behavior of Lipid Monolayer-Coated, Air-Filled Microbubbles: Effect of Lipid Hydrophobic Chain Length,” Langmuir, vol. 18, pp. 9225-9233, 2002. |
Bourke, Sharon L., and Joachim Kohn. “Polymers derived from the amino acid L-tyrosine: polycarbonates, polyarylates and copolymers with poly (ethylene glycol).” Advanced drug delivery reviews 55.4 (2003): 447-466. |
Brand, K. and Hermfisse, U., “Aerobic Glycolysis by Proliferating Cells: a Protective Strategy against Reactive Oxygen Species,” The FASEB Journal, vol. 11, pp. 388-395, Apr. 1997. |
Brentjens et al., “CD19-Targeted T Cells Rapidly Induce Molecular Remission in Adults with Chemotherapy-Refractory Acute Lympohblastic Leukemia,” Science Translational Medicine, vol. 5, Issue 177, pp. 1-9, Mar. 20, 2013. |
Brentjens et al., “Safety and Persistance of Adoptively Transferred Autologous CD19-Target T Cells in Patients with Relapsed or Chemotherapy Refractory B-Cell Leukemias,” Blood, vol. 118, No. 18, pp. 4817-4828, Nov. 3, 2011. |
C. H. Weaver, et al. An Analysis of Engraftment Kinetics as a function of the CD34 Content of the Peripheral Blood Progenitor Cell Collections in 692 Patients After the Administration of Myeloblative Chemotherapy. Blood 86(10): 3691-3969, 1995. |
Carswell, K. and Papoutsakis, E. “Culture of Human T Cells in Stirred Bioreactors for Cellular Immunotherapy Applications: Shear, Proliferation, and the IL-2 Receptor,” Biotechnology and Bioengineering, vol. 68, No. 3, pp. 329-338, May 5, 2000. |
Celeste Nelson et al., Emergent patterns of growth controlled by multicellular form and mechanics, (in Christopher Chen's Lab demonstrated, in separate experiments, that curved surfaces with a radius of curvature (200 ?m) that is greater than the cell diameter and surfaces that have undulating special patterning (depressions) increase the patterned growth of ECs [PNAS 102(33): 11594-11599, 2005]. |
Chapman NM, Chi H. mTOR signaling, Tregs and immune modulation. Immunotherapy. 2014;6(12):1295-311. |
Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Bruning JC, Muller W, Rudensky AY. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011;34(4):566-78. |
Chen, C. and Broden, M., “The Role of Poly(theylene glycol) Brush Architecture in Complement Activation on Targeted Microbubble Surfaces,” Biomaterials, vol. 32, No. 27, pp. 6579-6587, Jun. 17, 2011. |
Choi W, Kwon SJ, Jin HJ, et al. (2017) Optimization of culture conditions for rapid clinical-scale expansion of human umbilical cord blood-derived mesenchymal stem cells. Clin Transl Med 6(1): 38. |
Chullikana A, Majumdar AS, Gottipamula S, et al. (2015) Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy 17(3): 250-261. |
Claudio G. Brunstein, Jeffrey S. Miller, Qing Cao, Daivd H. Mckenna, Keli L. Hippen, Julie Curtsinger, Todd Defor, Bruce L. Levine, Carl H. June, Pablo Rubinstein, Philip B. McGlave, Bruce R. Blazar, and John E. Wagner. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood, 117(3): 1061-1070, 2010. |
Coeshott C, Vang B, Jones M, Nankervis B. Large-scale expansion and characterization of CD3(+) T-cells in the Quantum((R)) Cell Expansion System. J Transl Med. 2019;17(1):258. |
Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F. Regulatory T cells and intestinal homeostasis. Immunol Rev. 2005;204:184-94. |
Coquillard C. mTOR Signaling in Regulatory T cell Differentiation and Expansion. SOJ Immunology. 2015;3(1):1-10. |
Creed JA, DiLeonardi AM, Fox DP, Tessler AR, Raghupathi R. Concussive brain trauma in the mouse results in acute cognitive deficits and sustained impairment of axonal function. Journal of neurotrauma. 2011;28:547-563. |
Dash PK, Hochner B, Kandel ER. Injection of the camp-responsive element into the nucleus of aplysia sensory neurons blocks long-term facilitation. Nature. 1990;345:718-721. |
Dash PK, Johnson D, Clark J, Orsi SA, Zhang M, Zhao J, Grill RJ, Moore AN, Pati S. Involvement of the glycogen synthase kinase-3 signaling pathway in tbi pathology and neurocognitive outcome. PloS one. 2011;6:e24648. |
Dash PK, Mach SA, Blum S, Moore AN. Intrahippocampal wortmannin infusion enhances long-term spatial and contextual memories. Learn Mem. 2002;9:167-177. |
Dash PK, Orsi SA, Zhang M, Grill RJ, Pati S, Zhao J, Moore AN. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PloS one. 2010;5:e11383. |
Dash PK, Zhao J, Orsi SA, Zhang M, Moore AN. Sulforaphane improves cognitive function administered following traumatic brain injury. Neuroscience letters. 2009;460:103-107. |
Davila et al., “Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B cell Acute Lymphoblastic Leukemia,” Science Translational Medicine, vol. 6, No. 224, pp. 1-10, Feb. 19, 2014. |
Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and ve-cadherin in the control of vascular permeability. Journal of cell science. 2008;121:2115-2122. |
Dejana E, Spagnuolo R, Bazzoni G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thrombosis and haemostasis. 2001;86:308-315. |
Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: Molecular basis and pathological implications. Developmental cell. 2009;16:209-221. |
Del Pino A, Ligero G, Lopez MB, et al. (2015) Morphology, cell viability, karyotype, expression of surface markers and plasticity of three primary cell line cultures before and after the cryostorage in LN2 and GN2. Cryobiology 70(1): 1-8. |
Delaney, Colleen, et al. “Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution.” Nature medicine 16.2 (2010): 232-236. |
Ding, Zhongli, Guohua Chen, and Allan S. Hoffman. “Synthesis and purification of thermally sensitive oligomer? enzyme conjugates of poly (N-isopropylacrylamide)? trypsin.” Bioconjugate chemistry 7.1 (1996): 121-125. |
Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL. A controlled cortical impact model of traumatic brain injury in the rat. Journal of neuroscience methods. 1991;39:253-262. |
Dominici M, Le Blanc K, Mueller I, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4): 315-317. |
Durrani S, Konoplyannikov M, Ashraf M, Haider KH (2010) Skeletal myoblasts for cardiac repair. Regen Med 5(6): 919-932. |
Esensten JH, Muller YD, Bluestone JA, Tang Q. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier. J Allergy Clin Immunol. 2018;142(6):1710-1718. |
Fakin R, Hamacher J, Gugger M, Gazdhar A, Moser H, Schmid RA. Prolonged amelioration of acute lung allograft rejection by sequential overexpression of human interleukin-10 and hepatocyte growth factor in rats. Exp Lung Res. 2011;37(9):555-62. |
Fedorov et al., “PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses,” Science Translational Medicine, vol. 5, No. 215, pp. 1-12, Dec. 11, 2013. |
Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Next-generation regulatory T cell therapy. Nat Rev Drug Discov. 2019;18(10):749-769. |
Fischbach, Michael A., Jeffrey A. Bluestone, and Wendell A. Lim. “Cell-based therapeutics: the next pillar of medicine.” Science translational medicine 5.179 (2013): 179ps7-179ps7. |
Fisk, Nicholas M., et al. “Can routine commercial cord blood banking be scientifically and ethically justified?. ” PLoS medicine 2.2 (2005): e44. |
Forbes Jun. 23, 2014 article “Will this man cure cancer?”. |
Fowler DH. Rapamycin-resistant effector T-cell therapy. Immunol Rev. 2014;257(1):210-25. |
Fraser H, Safinia N, Grageda N, Thirkell S, Lowe K, Fry LJ, Scotta C, Hope A, Fisher C, Hilton R, Game D, Harden P, Bushell A, Wood K, Lechler RI, Lombardi G. A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials. Mol Ther Methods Clin Dev. 2018;8:198-209. |
Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, Elstrom RL, June CH, Thompson CB. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16(6):769-77. |
Fuchs A, Gliwinski M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhauser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Golab K, Hafler DA, van Ham SM, Hester J et al. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Front Immunol. 2017;8:1844. |
G0211: Study for Gamma Irradiation of Bioreactor Membranes, undated, author unknown, 3 pages. |
Galgani M, De Rosa V, La Cava A, Matarese G. Role of Metabolism in the Immunobiology of Regulatory T Cells. J Immunol. 2016;197(7):2567-75. |
Gedaly R, De Stefano F, Turcios L, Hill M, Hidalgo G, Mitov MI, Alstott MC, Butterfield DA, Mitchell HC, Hart J, Al-Attar A, Jennings CD, Marti F. mTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation. Transplantation. 2019;103(4):705-715. |
Gimble, Jeffrey M., Adam J. Katz, and Bruce A. Bunnell. “Adipose-derived stem cells for regenerative medicine.” Circulation research 100.9 (2007): 1249-1260. |
Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001; 15(7):807-26. |
Godin, Michel, et al. “Measuring the mass, density, and size of particles and cells using a suspended microchannel resonator.” Applied physics letters 91.12 (2007): 123121. |
Goh, Celeste, Sowmya Narayanan, and Young S. Hahn. “Myeloid-derived suppressor cells: the dark knight or the joker in viral infections?.” Immunological reviews 255.1 (2013): 210-221. |
Golab K, Leveson-Gower D, Wang XJ, Grzanka J, Marek-Trzonkowska N, Krzystyniak A, Millis JM, Trzonkowski P, Witkowski P. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int Immunopharmacol. 2013;16(3):371-5. |
Goldring CE, Duffy PA, Benvenisty N, Andrews PW, Ben-David U, Eakins R, French N, Hanley NA, Kelly L, Kitteringham NR, Kurth J, Ladenheim D, Laverty H, McBlane J, Narayanan G, Patel S, Reinhardt J, Rossi A, Sharpe M, Park BK. Assessing the safety of stem cell therapeutics. Cell stem cell. 2011;8:618-628. |
Griesche, Nadine, et al. “A simple modification of the separation method reduces heterogeneity of adipose-derived stem cells.” cells tissues organs 192.2 (2010): 106-115. |
Gutcher I, Donkor MK, Ma Q, Rudensky AY, Flavell RA, Li MO. Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiation. Immunity. 2011;34(3):396-408. |
Haack-Sorensen M, Follin B, Juhl M, et al. (2016) Culture expansion of adipose derived stromal cells. A closed automated Quantum Cell Expansion System compared with manual flask-based culture. J Transl Med 14(1): 319. |
Hall ED, Sullivan PG, Gibson TR, Pavel KM, Thompson BM, Scheff SW. Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: More than a focal brain injury. Journal of neurotrauma. 2005;22:252-265. |
Hami et al., “GMP Production and Testing of Xcellerated T Cells for the Treatment of Patients with CLL,” Cytotherapy, pp. 554-562, 2004. |
Hamm RJ, Dixon CE, Gbadebo DM, Singha AK, Jenkins LW, Lyeth BG, Hayes RL. Cognitive deficits following traumatic brain injury produced by controlled cortical impact. Journal of neurotrauma. 1992;9:11-20. |
Hanley PJ, Mei Z, Durett AG, et al. (2014) Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy 16(8): 1048-1058. |
He N, Fan W, Henriquez B, Yu RT, Atkins AR, Liddle C, Zheng Y, Downes M, Evans RM. Metabolic control of regulatory T cell (Treg) survival and function by Lkb1. Proc Natl Acad Sci U S A. 2017;114(47):12542-12547. |
He X, Landman S, Bauland SC, van den Dolder J, Koenen HJ, Joosten I. A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells. PLoS One. 2016;11(5):e0156311. |
Heskins, Michael, and James E. Guillet. “Solution properties of poly (N-isopropylacrylamide).” Journal of Macromolecular Science—Chemistry 2.8 (1968): 1441-1455. |
Hill JA, Feuerer M, Tash K, Haxhinasto S, Perez J, Melamed R, Mathis D, Benoist C. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity. 2007;27(5):786-800. |
Hollyman et al., “Manufacturing Validation of Biologicall Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy,” J Immunother, vol. 32, No. 2, pp. 169-180, Feb.-Mar. 2009. |
Horwitz, Mitchell E., et al. “Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide.” Journal of Clinical Oncology 37.5 (2019): 367-373. |
http://www.ucdenver.edu/academics/colleges/medicalschool/centers/cancercenter/Research/sharedresources/AnimalImaging/smallanimalimaging/Pages/MRI.aspx. |
ISCT Webinar “Volume Reduction technology for Large Scale Harvest or Post-thaw Manipulation of Cellular Therapeutics”. |
Iwashima, Shigejiro, et al. “Novel culture system of mesenchymal stromal cells from human subcutaneous adipose tissue.” Stem cells and development 18.4 (2009): 533-544. |
Jarocha D, Stangel-Wojcikiewicz K, Basta A, Majka M (2014) Efficient myoblast expansion for regenerative medicine use. Int J Mol Med 34(1): 83-91. |
Jin, H., and J. Bae. “Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow.” 22nd Annual ISCT Meeting (2016): S29. |
Jo CH, Lee YG, Shin WH, et al. (2014) Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells 32(5): 1254-1266. |
John Nicolette, et al (Abbott Laboratories). In Vitro Micronucleus Screening of Pharmaceutical Candidates by Flow Cyto9metry in Chinese Hamster V79 Cells, Environmental and Molecular Mutagenesis 00:000-000, 2010. |
Johnson, Patrick A., et al. “Interplay of anionic charge, poly (ethylene glycol), and iodinated tyrosine incorporation within tyrosine?derived polycarbonates: Effects on vascular smooth muscle cell adhesion, proliferation, and motility.” Journal of Biomedical Materials Research Part A: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials 93.2 (2010): 505-514. |
Johnston LC, Su X, Maguire-Zeiss K, Horovitz K, Ankoudinova I, Guschin D, Hadaczek P, Federoff HJ, Bankiewicz K, Forsayeth J. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol Ther. 2008;16(8):1392-9. |
Jones2016ISCT 2016 Poster 69. |
Joy, Abraham, et al. “Control of surface chemistry, substrate stiffness, and cell function in a novel terpolymer methacrylate library.” Langmuir 27.5 (2011): 1891-1899. |
Kalamasz et al., “Optimization of Human T-Cell Expansion Ex Vivo Using Magnetic Beads Conjugated with Anti-CD3 and Anti-CD28 Antibodies,” J Immunother, vol. 27, No. 5, pp. 405-418, Sep.-Oct. 2004. |
Kim, Do-Hyung, et al. “mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.” Cell 110.2 (2002): 163-175. |
Kishore M, Cheung KCP, Fu H, Bonacina F, Wang G, Coe D, Ward EJ, Colamatteo A, Jangani M, Baragetti A, Matarese G, Smith DM, Haas R, Mauro C, Wraith DC, Okkenhaug K, Catapano AL, De Rosa V, Norata GD, Marelli-Berg FM. Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. Immunity. 2017;47(5):875-889 e10. |
Klapper et al., “Single-Pass, Closed-System Rapid Expansion of Lymphocyte Cultures for Adoptive Cell Therapy,” Journal of Immunological Methods, 345, pp. 90-99, Apr. 21, 2009. |
Klysz D, Tai X, Robert PA, Craveiro M, Cretenet G, Oburoglu L, Mongellaz C, Floess S, Fritz V, Matias MI, Yong C, Surh N, Marie JC, Huehn J, Zimmermann V, Kinet S, Dardalhon V, Taylor N. Glutamine-dependent alpha-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci Signal. 2015;8(396):ra97. |
Korpanty et al., “Tageting Vascular Enothelium with Avidin Microbubbles,” Ultrasound in Medicine and Biology, vol. 31, No. 9, pp. 1279-1283, May 24, 2005. |
Krauss et al., “Signaling Takes a Breath—New Quantitative Perspectives on Bioenergetics and Signal Transduction,” Immunity, vol. 15, pp. 497-502, Oct. 2001. |
Kulikov, A. V., et al. “Application of multipotent mesenchymal stromal cells from human adipose tissue for compensation of neurological deficiency induced by 3-nitropropionic acid in rats.” Bulletin of experimental biology and medicine 145.4 (2008): 514-519. |
Kumar P, Marinelarena A, Raghunathan D, Ragothaman VK, Saini S, Bhattacharya P, Fan J, Epstein AL, Maker AV, Prabhakar BS. Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation. Cell Mol Immunol. 2019;16(2):138-153. |
Kwan, J. and Borden, M., “Lipid Monolayer Collapse and Microbubble Stability,” Advances in Colloid and Interface Science, vols. 183-184, pp. 82-99, Aug. 21, 2012. |
Lampugnani MG, Caveda L, Breviario F, Del Maschio A, Dejana E. Endothelial cell-to-cell junctions. Structural characteristics and functional role in the regulation of vascular permeability and leukocyte extravasation. Bailliere's clinical haematology. 1993;6:539-558. |
Lee et al., “Continued Antigen Stimulation Is Not Required During CD4+ T Cell Clonal Expansion,” The Journal of Immunology, 168, pp. 1682-1689, 2002. |
Lee III, Daniel W., et al. “Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation.” Blood 128.22 (2016): 218. |
Lee, Jae W., et al. “Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung.” Proceedings of the national academy of Sciences 106.38 (2009): 16357-16362. |
Levine, B., “T Lymphocyte Engineering ex vivo for Cancer and Infectious Disease,” Expert Opinion on Biological Therapy, vol. 4, No. 4, pp. 475-489, 2008. |
Lindstein, Tullia, et al. “Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway.” Science 244.4902 (1989): 339-343. |
Liotta, Francesco, et al. “Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma.” BJU international 107.9 (2011): 1500-1506. |
Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701-1711. |
Lum et al., “Ultrasound Radiation Force Enables Targeted Deposition of Model Drug Carriers Loaded on Microbubbles,” Journal of Controlled Release, 111, pp. 128-134, 2006. |
Malone et al., “Characterization of Human Tumor-Infiltrating Lymphocytes Expanded in Hollow-Fiber Bioreactors for Immunotherapy of Cancer,” Cancer Biotherapy & Radiopharmaceuticals, vol. 16, No. 5, pp. 381-390, 2001. |
Mao AS, Mooney DJ (2015) Regenerative medicine: current therapies and future directions. Proc Natl Acad Sci USA 112(47): 14452-14459. |
Maria Streltsova, Dean Lee (Nationwide Children's Hospital, OSU, Columbus, OH) et al (Int'l Journal of Molecular Sciences, 2019). |
Markgraf CG, Clifton GL, Aguirre M, Chaney SF, Knox-Du Bois C, Kennon K, Verma N. Injury severity and sensitivity to treatment after controlled cortical impact in rats. Journal of neurotrauma. 2001;18:175-186. |
Mathew et al. A Phase I Clinical Trials I with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants. Nature, Scientific Reports 8:7428 (1-12), 2018. |
Mathew, James M., et al. “A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants.” Scientific reports 8.1 (2018): 1-12. |
Matthay, Michael A., et al. “Therapeutic potential of mesenchymal stem cells for severe acute lung injury.” Chest 138.4 (2010): 965-972. |
Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY, Weaver CT. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3− precursor cells in the absence of interleukin 10. Nat Immunol. 2007;8(9):931-41. |
McKenna DH, Jr., Sumstad D, Kadidlo DM, et al. Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy 2017;19:250-62. |
McLimans W, Kinetics of Gas Diffusion in Mammalian Cell Culture Systems. Biotechnology and Bioengineering 1968; 10:725-740. |
McMurtrey, Richard J. “Analytic models of oxygen and nutrient diffusion, metabolism dynamics, and architecture optimization in three-dimensional tissue constructs with applications and insights in cerebral organoids.” Tissue Engineering Part C: Methods 22.3 (2016): 221-249. |
Menge, Tyler, et al. “Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury.” Science translational medicine 4.161 (2012): 161ra150-161ra150. |
Miska J, Lee-Chang C, Rashidi A, Muroski ME, Chang AL, Lopez-Rosas A, Zhang P, Panek WK, Cordero A, Han Y, Ahmed AU, Chandel NS, Lesniak MS. HIF-1alpha Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma. Cell Rep. 2019;27(1):226-237 e4. |
Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, Mathian A, Nakahata T, Yamaguchi T, Nomura T, Ono M, Amoura Z, Gorochov G, Sakaguchi S. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899-911. |
Nankervis B, Jones M, Vang B et al. (2018) Optimizing T Cell Expansion in a Hollow-Fiber Bioreactor. Curr Stem Cell Rep. Advanced online publication. https://doi.org/10.1007/s40778-018-0116-x. |
Nankervis, Brian, et al. “Optimizing T cell expansion in a hollow-fiber bioreactor.” Current Stem Cell Reports 4.1 (2018): 46-51. |
Nedoszytko B, Lange M, Sokolowska-Wojdylo M, Renke J, Trzonkowski P, Sobjanek M, Szczerkowska-Dobosz A, Niedoszytko M, Gorska A, Romantowski J, Czarny J, Skokowski J, Kalinowski L, Nowicki R. The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis. Postepy Dermatol Alergol. 2017;34(5):405-417. |
Nehlin JO, Just M, Rustan AC (2011) Human myotubes from myoblast cultures undergoing senescence exhibit defects in glucose and lipid metabolism. Biogerontology 12: 349-365. |
New victories for adult Stem Cell Research New York Feb. 6, 2007. |
Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells. Nat Immunol. 2016;17(6):618-25. |
Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol. 2013;4:129. |
Nikolaychik, V. V., M. M. Samet, and P. I. Lelkes. “A New, Cryoprecipitate Based Coating For Improved Endothelial Cell Attachment And Growth On Medical Grade Artificial Surfaces.” ASAIO Journal (American Society for Artificial Internal Organs: 1992) 40.3 (1994): M846-52. |
Nish SA, Schenten D, Wunderlich FT, Pope SD, Gao Y, Hoshi N, Yu S, Yan X, Lee HK, Pasman L, Brodsky I, Yordy B, Zhao H, Bruning J, Medzhitov R. T cell-intrinsic role of IL-6 signaling in primary and memory responses. Elife. 2014;3:e01949. |
Niwayama, Jun, et al. “Analysis of hemodynamics during blood purification therapy using a newly developed noninvasive continuous monitoring method.” Therapeutic Apheresis and Dialysis 10.4 (2006): 380-386. |
Okano et al (Tokyo Women's Medical College, Japan) demonstrated the recovery of endothelial cells and hepatocytes from plasma-treated polystyrene dishes grafted with PNIAAm (Journal of Biomedical Materials Research, 1993). |
Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008;105(29):10113-8. |
Onyszchuk G, LeVine SM, Brooks WM, Berman NE. Post-acute pathological changes in the thalamus and internal capsule in aged mice following controlled cortical impact injury: A magnetic resonance imaging, iron histochemical, and glial immunohistochemical study. Neuroscience letters. 2009;452:204-208. |
Pacella I, Procaccini C, Focaccetti C, Miacci S, Timperi E, Faicchia D, Severa M, Rizzo F, Coccia EM, Bonacina F, Mitro N, Norata GD, Rossetti G, Ranzani V, Pagani M, Giorda E, Wei Y, Matarese G, Barnaba V, Piconese S. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc Natl Acad Sci U S A. 2018;115(28):E6546-E6555. |
Parhi, Purnendu, Avantika Golas, and Erwin A. Vogler. “Role Of Proteins And Water In The Initial Attachment Of Mammalian Cells To Biomedical Surfaces: A Review.” Journal of Adhesion Science and Technology 24.5 (2010): 853-888. |
Pati S, Gerber MH, Menge TD, Wataha KA, Zhao Y, Baumgartner JA, Zhao J, Letourneau PA, Huby MP, Baer LA, Salsbury JR, Kozar RA, Wade CE, Walker PA, Dash PK, Cox CS, Jr., Doursout MF, Holcomb JB. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PloS one. 2011;6:e25171. |
Pati S, Khakoo AY, Zhao J, Jimenez F, Gerber MH, Harting M, Redell JB, Grill R, Matsuo Y, Guha S, Cox CS, Reitz MS, Holcomb JB, Dash PK. Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/beta-catenin signaling. Stem cells and development. 2011;20:89-101. |
Pati, Shibani, and Todd E. Rasmussen. “Cellular therapies in trauma and critical care medicine: Looking towards the future.” PLoS Medicine 14.7 (2017): e1002343. |
Pati, Shibani, et al. “Lyophilized plasma attenuates vascular permeability, inflammation and lung injury in hemorrhagic shock.” PloS one 13.2 (2018): e0192363. |
Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJ, Joosten I. Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation. PLoS One. 2008;3(9):e3161. |
Peters, R.; Jones, M.; Brecheisen, M.; Startz, T.; Vang, B.; Nankervis, B.; Frank, N.; Nguyen, K. (2012) TerumoBCT. https://www.terumobct.com/location/north-america/products-and-services/Pages/Quantum-Materials.aspx. |
Porter CM, Horvath-Arcidiacono JA, Singh AK, Horvath KA, Bloom ET, Mohiuddin MM. Characterization and expansion of baboon CD4+CD25+ Treg cells for potential use in a non-human primate xenotransplantation model. Xenotransplantation. 2007;14(4):298-308. |
Povsic TJ, O'Connor CM, Henry T, et al. (2011) A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am Heart J 162(4): 654-662. |
Prockop, Darwin J., Carl A. Gregory, and Jeffery L. Spees. “One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues.” Proceedings of the National Academy of Sciences 100.suppl_1 (2003): 11917-11923. |
Q. L. Hao, et al. A functional comparison of CD34+ CD38= cells in cord blood and bone marrow. Blood 86:3745-3753, 1995. |
Rahmahwati, Nurlaela, Deana Wahyuningrum, and Anita Alni. “The Synthesis Of Polyethersulfone (PES) Derivatives For The Immobilization Of Lipase Enzyme.” Key Engineering Materials. vol. 811. Trans Tech Publications Ltd, 2019. |
Rey-Jurado, Emma, et al. “Assessing the importance of domestic vaccine manufacturing centers: an overview of immunization programs, vaccine manufacture, and distribution.” Frontiers in immunology 9 (2018): 26. |
Roballo KC, Dhungana S, Z. J, Oakey J, Bushman J. Localized delivery of immunosuppressive regulatory T cells to peripheral nerve allografts promotes regeneration of branched segmental defects. Biomaterials. 2019;209:1-9. |
Ronco C1, Levin N, Brendolan A, Nalesso F, Cruz D, Ocampo C, Kuang D, Bonello M, De Cal M, Corradi V, Ricci Z. Flow distribution analysis by helical scanning in polysulfone hemodialyzers: effects of fiber structure and design on flow patterns and solute clearances. Hemodial Int. Oct. 2006; 10(4):380-8. |
Rosenblum MD, Way SS, Abbas AK. Regulatory T cell memory. Nat Rev Immunol. 2016;16(2):90-101. |
Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, Roers A, Henderson WR, Jr., Muller W, Rudensky AY. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28(4):546-58. |
Rudensky, Alexander Y. “Regulatory T cells and Foxp3.” Immunological reviews 241.1 (2011): 260-268. |
S. Koestenbauer, et al. Protocols for Hematopoietic Stem Cell Expansion from Umbilical Cord Blood. Cell Transplantation 18: 1059-1068, 2009. |
S. L. Smith, et al. Expansion of neutrophil precursors and progenitors in suspension cultures of CD34+ cells enriched from human bone marrow. Experimental Hematology 21:870-877, 1993. |
Safinia N, Grageda N, Scotta C, Thirkell S, Fry LJ, Vaikunthanathan T, Lechler RI, Lombardi G. Cell Therapy in Organ Transplantation: Our Experience on the Clinical Translation of Regulatory T Cells. Front Immunol. 2018;9:354. |
Sahay A, Scobie KN, Hill AS, O'Carroll CM, Kheirbek MA, Burghardt NS, Fenton AA, Dranovsky A, Hen R. Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature. 2011;472:466-470. |
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151-64. |
Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18-32. |
Schild, Howard G. “Poly (N-isopropylacrylamide): experiment, theory and application.” Progress in polymer science 17.2 (1992): 163-249. |
Schmitz R, Alessio A, Kina P. The Physics of PET/CT scanners. Imaging Research Laboratory, Department of Radiology, University of Washington http://depts.washington.edu/imreslab/education/Physics%20of%20PET.pdf. |
Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305-34. |
Shevkoplyas et al., “The Force Acting on a Superparamagnetic Bead due to an Applied Magnetic Field,” Lab on a Chip , 7, pp. 1294-1302, 2007. |
Shimazu Y, Shimazu Y, Hishizawa M, Hamaguchi M, Nagai Y, Sugino N, Fujii S, Kawahara M, Kadowaki N, Nishikawa H, Sakaguchi S, Takaori-Kondo A. Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia. Cancer Immunol Res. 2016;4(2):136-45. |
Sigma-Aldrich Cheimcals Mitomycin C (M4287) MSDS, v4.4, Jul. 7, 2011. |
Sirsi, S. and Borden, M., “Microbubble Composition, Properties, and Biomedical Applications,” Bubble Science, Engineering & Technolology, vol. 1, No. 1-2, pp. 3-17, 2009. |
Smith C, Okern G, Rehan S, et al. Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement. Clinical & Translational Immunology 2015;4:e31. |
Somerville et al., “Clinical Scale Rapid Expansion of Lymphocytes for Adoptive Cell Transfer Therapy in the WAVE® Bioreactor,” Journal of Translational Medicine, vol. 10, No. 69, pp. 1-11, 2012. |
Somerville, R. and Dudley, M., “Bioreactors Get Personal,” Oncolmmunology, vol. 1, No. 8, pp. 1435-1437, Nov. 2012. |
Spectrum Labs KrosFlo Research Ili TFF System, undated, Spectrum Laboratories, Inc., 4 pages. |
Stafano Tiziani, et al. Metabolomic Profiling of Drug Response in Acute Myeloid Leukaemia Cell lines. PLOSone 4(1): e4251 (Jan. 22, 2009). |
StAR_Abstract, undated, author unknown, 1 page. |
Startz et al.May 2016 TBCT T-cell White Paper. |
Startz, T., et al. “Maturation of dendritic cells from CD14+ monocytes in an automated functionally closed hollow fiber bioreactor system.” Cytotherapy 16.4 (2014): S29. |
Steven M. Bryce, et al (Litron Laboratories). In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. Mutation Research 630(1-2): 78-91, 2007. |
Steven M. Bryce, et al (Novartis Pharma AG, Johnson & Johnson Pharmaceutical Research, GlaxoSmithKline). Interlaboratory evaluation of a flow cytometric, high content in vitro micronucleus assay. Genetic Toxicology and Environmental Mutagenesis 650: 181-195, 2008. |
Stuart, Martien A. Cohen, et al. “Emerging applications of stimuli-responsive polymer materials.” Nature materials 9.2 (2010): 101-113. |
Su LF, Del Alcazar D, Stelekati E, Wherry EJ, Davis MM. Antigen exposure shapes the ratio between antigen-specific Tregs and conventional T cells in human peripheral blood. Proc Natl Acad Sci U S A. 2016;113(41):E6192-E6198. |
Trzonkowski et al., “Ex Vivo Expansion of CD4+ CD25+ T Regulatory Cells for Immunosuppressive Therapy,” Cytometry Part A, 75A, pp. 175-188, 2009. |
Trzonkowski, Piotr, et al. “First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+ CD25+ CD127? T regulatory cells.” Clinical immunology 133.1 (2009): 22-26. |
Tsvetkov, Ts, et al. “Isolation and cryopreservation of human peripheral blood monocytes.” Cryobiology 23.6 (1986): 531-536. |
Underwood, P. Anne, et al. “Effects of base material, plasma proteins and FGF2 on endothelial cell adhesion and growth.” Journal of Biomaterials Science, Polymer Edition 13.8 (2002): 845-862. |
Van der Net JB, Bushell A, Wood KJ, Harden PN. Regulatory T cells: first steps of clinical application in solid organ transplantation. Transpl Int. 2016;29(1):3-11. |
Van der Windt GJ, Pearce EL. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol Rev. 2012;249(1):27-42. |
Vera et al., “Accelerated Production of Antigen-Specific T-Cells for Pre-Clinical and Clinical Applications Using Gas-Permeable Rapid Expansion Cultureware (G-Rex),” J Immunother, vol. 33, No. 3, pp. 305-315, Apr. 2010. |
Villa, Alma Y. Camacho, et al. “CD133+ CD34+ and CD133+ CD38+ blood progenitor cells as predictors of platelet engraftment in patients undergoing autologous peripheral blood stem cell transplantation.” Transfusion and Apheresis Science 46.3 (2012): 239-244. |
Visser EP1, Disselhorst JA, Brom M, Laverman P, Gotthardt M, Oyen WJ, Boerman OC. Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med. Jan. 2009;50(1):139-47. |
Wagner Jr, John E., et al. “Phase I/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft.” Cell stem cell 18.1 (2016): 144-155. |
Walker, Peter A., et al. “Direct intrathecal implantation of mesenchymal stromal cells leads to enhanced neuroprotection via an NF?B-mediated increase in interleukin-6 production.” Stem cells and development 19.6 (2010): 867-876. |
Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger J, Green DR. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35(6):871-82. |
Wang, Jiamian, John A. Jansen, and Fang Yang. “Electrospraying: possibilities and challenges of engineering carriers for biomedical applications—a mini review.” Frontiers in Chemistry 7 (2019): 258. |
Ward H, Vigues S, Poole S, Bristow AF. The rat interleukin 10 receptor: cloning and sequencing of cDNA coding for the alpha-chain protein sequence, and demonstration by western blotting of expression in the rat brain. Cytokine. 2001;15(5):237-40. |
Wawman, Rebecca Ellen, Helen Bartlett, and Ye Htun Oo. “Regulatory T cell metabolism in the hepatic microenvironment.” Frontiers in immunology 8 (2018): 1889. |
Weber et al., “White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy,” Clinical Cancer Research, vol. 17, No. 7, pp. 1664-1673, Apr. 1, 2011. |
Weiss RA, Weiss MA, Beasley KL, Munavalli G (2007) Autologous cultured fibroblast injection for facial contour deformities: a prospective, placebo-controlled, Phase III clinical trial. Dermatol Surg 33(3): 263-268. |
Widdel, F. 2010. “Theory and measurement of bacterial growth” http://www.mpi-bremen.de/Binaries/Binary13037/Wachstumsversuch.pdf. |
Yamada, Noriko, et al. “Thermo?responsive polymeric surfaces; control of attachment and detachment of cultured cells.” Die Makromolekulare Chemie, Rapid Communications 11.11 (1990): 571-576. |
Yoshinari, Masao, et al. “Effect of cold plasma-surface modification on surface wettability and initial cell attachment.” International Journal of Biomedical and Biological Engineering 3.10 (2009): 507-511. |
Zappasodi et al., “The Effect Of Artificial Antigen-Presenting Cells with Preclustered Anit-CD28/-CD3/LFA-1 Monoclonal Antibodies on the Induction of ex vivo Expansion of Functional Human Antitumor T Cells,” Haematologica, vol. 93, No. 10, pp. 1523-1534, 2008. |
Zemmour D, Zilionis R, Kiner E, Klein AM, Mathis D, Benoist C. Publisher Correction: Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR. Nat Immunol. 2018;19(6):645. |
Zeng B, Kwak-Kim J, Liu Y, Liao AH. Treg cells are negatively correlated with increased memory B cells in pre-eclampsia while maintaining suppressive function on autologous B-cell proliferation. Am J Reprod Immunol. 2013;70(6):454-63. |
Examination Report for related European Patent Application No. 17803614.1; dated Mar. 10, 2023; 5 pages. |
Doran, M., Cell Transplantation, Cognizant Comm. Corp., vol. 21 (6), pp. 1235-1244, Jun. 2012. |
Chinese Office Action for related Chinese Application No. 201780040488.2; dated May 12, 2023; 8 pages. |
Pankaj Godara et al., Design of Bioreactors for Mesenchymal Stem Cell Tissue Engineering, Journal of Chemical Technology and Biotechnology, vol. 83, pp. 408-420, Feb. 2008. |
Number | Date | Country | |
---|---|---|---|
20190119628 A1 | Apr 2019 | US |
Number | Date | Country | |
---|---|---|---|
62341523 | May 2016 | US |